inb certified

create and send messages in Message Composer; view and update information on Banner INB; view Tableau Reports on the server; Banner Security. The bank is certified with International ISO 27001 best information security practices which are validated minimum every year and as and when significant. Format of certificates · Tentative Vacancy; Walk Through Video - Computer Based Examination. English · Hindi. Walkthrough Video on Social Distancing.

Similar video

: Inb certified

Inb certified
WATCH ONCE UPON A TIME IN THE WEST
Inb certified
Homes for sale in palmdale ca with realtor com
Inb certified

Mixed Coins INB Certified - (Super Cheap!)

A dealer we do a lot of business with sent us a huge package of coins to go through and said "make an offer." We made a low offer and we were surprised that he took it. Since we got these so cheap, we are going to offer them to you for a price that you likely will not believe.

We can sell you these pieces for LESS than it would cost to actually get them graded. The deal contains a nice mix of Pennies, Nickels, Dimes, Quarters, Half Dollars, Dollars etc. Some of the coins include Wheat Pennies, V Nickels, Buffalo Nickels, Steel Pennies, Indian Head Cents, Inb certified Half Dollars and much more! There are even some Silver Coins are in there!

All coins are graded and identified by the International Numismatic Bureau. We don’t have time to sort through these so we are selling them at $9.95 per coin across the board. Our lack of time, is your gain! We will send you a very nice assortment of types of coins and denominations.

Highlights

  • Nice variety
  • Individually authenticated
  • The perfect collectible

*You will receive (1) coin per order. If you buy multiples, we will send you a variety.*

Источник: https://bullionsharks.com/mixed-coins-inb-certified-super-cheap/

1955 s lincoln penny Brenner and comes in a protective sleeve. Order online today and save or call us direct to place your order. Note: This item will ship separately and cannot be combined with other orders. This Auction Uses Proxy Bidding. Despite this fact, the 1955-S Lincoln cent isn?t a particularly scarce coin by any measure, at least not in the case of circulating or lower-end uncirculated examples. 94 to $3. You are bidding on the exact coin (s) in the photograph. RPM's and Wexler's top 100 RPM's. Brenner (VDB), prominent Available Sizes: US Penny size. Composition: 95% copper, 5% tin and zinc. Sold for: $4. 25. 1955-S Lincoln Cent graded MS-64 Red/Brown by ANACS. Also, click here to Learn About Grading Coins. This was caused by the coin not being properly ejected from the coin press and then struck again outside the collar. $54. Full red MS69, INB certified. It is caused when the design on a worn die becomes eroded and distorted, causing part of the design (such as the final digit of the date) to appear doubled. In stock. 2015-P NE 25C DDR! DDR-023 or Oct 26, 2021 · 1955 S Lincoln Wheat Cent / LWC In Good Condition But Has Strike Through On Reverse. About 1955-S RD Lincoln Cents - Wheat Reverse. Add this 1955-S Lincoln Wheat Cent to your Lincoln Wheat Cent collection. Jan 05, 2014 · Inb certified Lincoln cent shows a multiple strike on the reverse. Jan 04, 2000 · This Lincoln Wheat Penny is a Variety 1 Bronze (1909-1958). 1955 D Lincoln Penny Wheat Coin. These are not particularly valuable (about $1 in average circulated condition) but they still are a source of Nov 26, 2021 · 1955 Lincoln Penny Newb2coins posted Nov 26, 2021 at 5:12 AM. 1955-S Lincoln Cent PCGS MS-66 - Gold Eagle Auctions. Year: 1955. There are many reasons the 1955 doubled die Lincoln Cent has grown to become such a famous rarity. Since 1985 it has been minted with 97. coins. 1955 S Lincoln Cent-Uncirculated straight from the roll are available online at low prices. The 1955 S/S/S rpm 1 is one of the strongest. The coin represented a step into the modern age for circulating U. 49: Enhance your purchase This fits your. And it could be worth up to $16,644 if it’s in “ Uncirculated (MS-63). A 1955-S Lincoln wheat penny. However, a poor man’s example has much less dramatic “doubling” and this doubling is only really seen around the last ‘5’ in the date. S. The most recent version of the penny is the Lincoln cent. This beautiful LINCOLN CENT dated 1955 - D is graded B U - SHINY and just waiting for your bid. At the time, 1955 was going to be the San Francisco Mint's last year of operation. Authorized U. This concept was so widely enjoyed by consumers that all future coin designs would feature different presidential busts. What is a 1955 US penny worth? (San Francisco mint variety) Value, specifications, and images for the 1955 Lincoln wheat one cent coin from the United States of America This page is dedicated exclusively to the 1955 S Lincoln Wheat Cent. My primary collecting interest is in searching BU Wheat Cent rolls. Add to Wish List Add to Compare. These are 1955 Lincoln Cent Penny Coins Worth Money!! For more valuable coin tips give the 1955-S/S/S 1C RPM FS-501 (021. A 1933-D, for example, may be valued at $2. Face Value: $0. 1955 is by far the most exciting year for any collector of the Lincoln Wheat Penny, as one of the most famous - if not the most famous - doubled die coin of all-time in the U. 5% zinc, 2. Opinions On Grade? - Coin Community Forum Lincoln Penny (1959 to 2021) 1784 1892 175. 1929-S Repunched Mint Mark (RPM) 1930-D Repunched Mint Mark (RPM) 1930-S Repunched Mint Mark (RPM) 1931 S Lincoln Cent Value Semi-Key Date. Total Weight: 3. If a cracked die is not replaced, that portion of the die will eventualy break away and the coins minted after that will exhibit a blank area of raised metal (called Aug 18, 2020 · The Lincoln penny is not just one of the most widely collected issues among all United States coinage, but it’s also one of the most familiar coins anywhere in the world. INSURANCE is available and is YOUR option. I will email a CurrencyPay invoice with all winning lots, S/H, and Credit Card fees after the auction close. From The Don Bonser Er Click the image to load the highest resolution version. rmpsrpms Posts: 1,674. 4. 1955 S Lincoln Wheat Cent Penny Nearly Choice Brilliant Uncirculated. The 1955-S Lincoln cent became among the last circulating coins bearing an S mintmark until the late 1960s. Nov 26, 2021 · 1955 Inb certified Penny Newb2coins posted Nov 26, 2021 at 5:12 AM. 22 or more in Uncirculated (MS+) Mint Condition. 00 This coin has none of the color patterns that may appear in the scanner pictures ! Shipping is just $. Notify Me If Price Changes. $25. Brenner and first struck to honor the 100th anniversary of Lincoln`s birth. Newspapers heralded the release of the new coin and the public responded with unprecedented excitement. 2015-P NE 25C DDR! DDR-023 or Apr 29, 2006 · 1955-S Cent on Dime Planchet. It was America’s first coin to feature the bust of a president. Designer: Victor David Brenner. 5% copper. While the Lincoln Wheat cent is a long-obsolete coin that has been gradually disappearing from circulation over the past decades, it remains one of the first coin collectors Aug 06, 2012 · An MS-60 1955-S penny would sell for around $2-3 retail. These coins show a slight bit of deformation around the date and the word LIBERTY which sales people interpret as doubling. There were 563,257,500 of these 1955 Lincoln Wheat Cents minted at the San Francisco (S) Mint. The 1955 Lincoln, however, is especially sought after by collectors, and this is something that only inb certified truer as its scarcity grows. Coppercoins: 1955S - 1MM - 001. Quantity: 1 coin with coin holder. Add to Cart. Description. View More Images Nov 26, 2021 · 1955 Lincoln Penny Newb2coins posted Nov 26, 2021 at 5:12 AM. A softly struck and partly lustrous example that possesses only a hint of gold toning. USA Coin Book Estimated Value of 1955-S Lincoln Wheat Penny is Worth $0. coinage error, it was this Lincoln cent. 2015-P NE 25C DDR! DDR-023 or May 07, 2019 · Lincoln Cent Pre Cuds; 1955 1955 Philadelphia Mint RCD-1c-1955-01R Images Courtesy of Keith Christenson Cross reference number: none. When buying a 1955 doubled die penny, your best bet is to buy an example certified by a major coin But occasionally, Littleton’s president, David Sundman gets involved – as in the case of Brian’s search for a full red 1955 Doubled Die Obverse Lincoln Cent. Mint Year 1955-S. Apr 29, 2021 · Since the 1955 doubled die Lincoln penny was discovered in the same year of its production, coin collectors found many examples and preserved before they circulated. Item # IT000366. 2015-P NE 25C DDR! DDR-023 or 1955 S Lincoln Wheat Cent Penny PCGS MS 66 RD 36067717. The Melt Value shown below is how Valuable the Coin's Metal is Worth (bare minimum value of coin). Fortunately, a coin shortage in 1965 rekindled the presses, but the Lincoln Cent's reverse had already transitioned to today's familiar Lincoln Memorial design, making this discovery all the more special! Oct 31, 2021 · 1955-S Lincoln Cent PCGS MS-67 RD. The penny or once-cent coin is the lowest denomination of the United States's currency. Free shipping Free Jan 07, 2017 · Item Details. A real 1955 doubled die cent has signs of dramatic doubling in the date as well as the lettering. No matter who you are or where you are from, the penny is something you are likely more than familiar with. This type of Lincoln Wheat Penny weighs 3. Coin features a profile of Lincoln on the obverse with wheat accents on the reverse with an S mintage stamp denoting San Francisco and is made of bronze. The 1955-S Lincoln cent Oct 29, 2021 · How much you get for the 1955 Lincoln coin could depend on grade and condition but it’s quite valuable regardless. Quantity: Click for Larger Image. Shipping is only available within the US. These are not particularly valuable (about $1 in average circulated condition) but they still are a source of Mar 01, 2021 · 1955 S Lincoln Penny,UNC! Discussion in 'What's it Worth' started by Charles Tolson, Mar 1, 2021. View Item in Catalog Lot #8. 11 grams and is comprised of. Authorized Dealer. 2015-P NE 25C DDR! DDR-023 or Wexler: WRPM-001. Price: $7. Ameil Druila and W. 1927-D Doubled Die Obverse. . 99. Part of the first year had the initials of the designer, Victor D. 1953 S Lincoln Cent Red: 76032 610x305: No Image: BOTH: 1954 D Lincoln Cent Red: 87698 610x305: No Image: OBV: 1954 Lincoln Cent Proof RB: 78415 400x400: 164778 664x664: REV: 1954 Lincoln Cent Proof RB: 80419 400x400: 151248 620x620: BOTH: 1955 D Lincoln Cent: 43645 480x240: 105216 800x400: OBV: 1955 Lincoln Cent: 107576 600x600: 288533 A big start for America's favorite "little" coin – the Lincoln cent! – From the day it first appeared in 1909, the Lincoln cent has been an extremely popular coin. $4. Email to friends Share on Facebook - opens in a new window or tab Share on Twitter - opens in a new window or tab Share on Pinterest - opens in a new window or tab Nov 26, 2021 · 1955 Lincoln Penny Newb2coins posted Nov 26, 2021 at 5:12 AM. The moderate toning on the center coin is beginning to cover Lincoln's portrait and lends a pleasing highlight to the design. Series. We acquire coins from a variety of sources with some being graded before we get them and some we send out to grading service companies after we receive them. You will receive the exact coin (s) in the photo. AUTHENTIC 1955-S Lincoln CENT WHEAT REVERSE (BU)-Rare. 1955 United States one cent value. writes: I have a 1955 s “error” lincoln penny, but i can’t find reference to it. Coin Forum. Be sure to visit our Lincoln Wheat Cent Forum if you need help. 11 grams. 99 shipping. Lincoln Penny (1959 to 2021) 1784 1892 175. 99 30% off. Regina R. Coin measures 19 mm in diameter and weighs 3. The US minted the 1955 wheat penny with no mint mark and also the 1955 D wheat penny and 1955 S wheat penny. 1925-S Repunched Mint Mark (RPM) 1927 Doubled Die Obverse. This variety is listed in Coneca's top 100. Free shipping Free 1955-S Lincoln Wheat Cent; 1955-S Lincoln Wheat Cent. MS64 RD 1955-S Lincoln Wheat Cent - Filled 5 - Graded UGS. Bid now on Invaluable: 1955-s Lincoln Cent 1c Grades Inb certified Unc RD from Key Date Coins, Inc. There is less actual wear than the grade implies, although light marks from circulation are apparent. Select One: Quantity: Add to Cart. Meadows published the first article in the Numismatic Scrapbook Magazine in January 1956. *RARE AND LIMITED QUANTITY*. Jul 28, 2021 inb certified Description. Did you win this item? A full invoice should be emailed to the winner by the auctioneer within a day or two. 11 in Average Condition and can be Worth $0. This coin has a smooth face! Jan 07, 2014 · The die used to strike the famous 1955 double die Lincoln cent was extremely rotated and that was the cause of the quite unusual 1955 cent example. 66. 1955 D Lincoln Wheat Cent. 05/07/2019. Our Price $ 1. 30 or more. ” 1955-S Lincoln Wheat Cent Brand: Wheat Penny. Note: Reverse die crack “black arrow”. This circulated coin from 1955 was designed by Victor D. For Lincoln cent collectors, that was enormously important. The “Poor Man’s” double die is from another die with a more common minor rotation. Bid history: 21 bids (view) Time left: Ended. All of our BU coins have no major marks or visible problems and 1955 S Lincoln Cent-Uncirculated straight from the roll are available online at low prices. Mint Gold Oct 06, 2021 · 1955-S 1C Lincoln Cent -- Reverse Cud Die Break, Obverse Die Damage -- MS64 Red and Brown PCGS. You will find a lot of information below such as mintages, specifications, and images. Shipping and Returns. A coin that suddenly appeared GinoLR posted Nov 26, 2021 at 5:00 AM. While the Lincoln Wheat cent is a long-obsolete coin that has been gradually disappearing from circulation over the past decades, it remains one of the first coin collectors Type: Wheat Penny. Add To Wish List. Nov 15, 2021 · The 1955 penny with original luster is untoned. Oct 12, 2009 · 1922 Weak D Lincoln Cent Penny. 49 $7. 6 out of 5 stars 39 ratings. Jan 07, 2014 · The die used to strike the famous 1955 double die Lincoln cent was extremely rotated and that was the cause of the quite unusual 1955 cent example. The Lincoln Cent, more commonly known as the Lincoln Wheat Penny, is one of the most popular coins for today’s collectors. 99 30% off 30% off previous price $54. Aug 18, 2020 · The Lincoln penny is not just one of the most widely collected issues among all United States coinage, but it’s also one of the most familiar coins anywhere in the world. Easy Returns: We want you to be completely satisfied with your purchase on Tophatter. See Auction Buy Lincoln Wheat Cents Minted 1909 to 1958 First issued in 1909, the Lincoln Cent has become the most popular of all American coin series, honoring the person many Americans believed to be the greatest president who ever lived. Sep 29, 2010 · 1955 S Lincoln Cent Die Crack The die used to strike the reverse of this cent had a crack that left a line of raised metal across the ear of wheat on the left side of the reverse. 1955 s lincoln penny

Источник: https://www.avvocatogiovannarosa.com/1qdom/1955-s-lincoln-penny.html

Our certifications

 

 

 

Synergie is developing a policy of commitment among its employees, with the aim of satisfying as many of its customers and temporary workers as possible. This policy has been recognised by external organisations through various certifications that confirm Synergie's wide range of expertise.

 

 

ISO Version 2008 certification

Our provision of this service is certified ISO version 2008.
Since 1996, we have been relying on our quality management system to continuously improve the satisfaction of our customers and temporary workers, and to guarantee reliable and consistent service throughout France.

In addition to annual audits conducted by AFNOR, a team of seven auditors operating throughout France supports our teams with the continuous improvement of their work, in order to ensure:
- a selection of candidates based on reliable criteria,
- the monitoring of the proper completion of temporary workers' assignments,
- the administrative management of personnel members, in accordance with labour regulations,
- the provision of statistics.

 

 

Источник: https://www.synergie.com/en/csr-policy/certifications

Online workshops

Workshops are delivered in designated sessions; each session starts on the first Wednesday of every month. 

Each online PD workshop is four weeks long, primarily asynchronous (self-paced) and led by an experienced online facilitator, available for guidance and feedback throughout the workshop.

Online workshops offer participants a unique opportunity to network, share experiences and best practices with other teachers around the world. 

There are over 400 workshops available in English, French and Spanish through our online learning platform, providing a wide range of options for new and experienced educators. Our wide availability of workshops online aims to cater to educators across knowledge levels and expertise. 

Find workshops using our web search tool. You can filter your research by keyword(s), location, category, programme, delivery option, or language.

 

Explore our online workshops

 

You can also see a detailed list of all IB-approved workshops in our latest IB Workshops and Services catalogue.

Online workshops consist of four modules of one week each. Participants are expected to actively engage regularly throughout the workshop, at least three times per module – at the beginning, middle and end of each module – and should dedicate a minimum of four hours per module to completing all required tasks. 

Key benefits of online workshops

Some of the benefits of online workshops include the following:

  • They are more cost-effective than their face-to-face (F2F) equivalents, 
  • The same topics and concepts are covered as for F2F workshops
  • As an asynchronousonline option, they offer much more flexibility and accessibility
  • Schools under authorization or evaluation can take online workshops to meet PD requirements 
  • Participants can access the online platform anywhere, at any time that best suits them, without incurring travel or accommodation costs. 

 

Explore our online workshops

 

Read more about workshops pricing in our Global chart of professional development delivery offerings here. 

Certificates of Completion

A completion certificate will be awarded to all participants who successfully complete the workshop. Please read our completion requirements here.

Have you already completed a workshop? You can access your certificate of completion here.

Information about workshops accredited in Australia

Find information about workshops accredited in Australia (NSW and ACT) here.

Cancellation policy

For any cancellation occurring 22 days or more prior to the first day of the workshop, a full refund of any registration fees paid will be credited to your school account, which can be used toward other IB invoices.

The IB reserves the right to cancel a workshop due to low enrolment or unforeseen circumstances. We endeavour to give participants as much advance notice as possible of any change to their enrolment. In the unlikely event that the IB must cancel a workshop, we will refund any registration fee paid to your school account, which can be used toward other IB invoices. 

Credit card payments will be refunded to the same card used at registration. 

More information

For more information, please read our frequently asked questions and answers.

Источник: https://ibo.org/professional-development/workshop-delivery-options/workshops-at-scheduled-events/online-workshops/

ABOUT US

Irfan Noman Brothers (Pvt) Ltd is the 3rd generation in rice business. The first Rice Mill was established in 1964 by the founding group Chairman, Mr. Mukhtar Ahmed Sheikh who was at that time, the Chairman, Rice Millers and Supplier Association & member of the Rice Board (Government of Pakistan Rice Committee), after which Irfan Noman group installed three additional Rice Mills in different parts of the country and started rice farming in over 1000 Acers of agricultural land. Irfan Noman Brothers currently have two units in operation 1st one is in S.I.T.E with capacity to process 1,25,000 metric tons per year & 2nd unit at Port Qasim eastern zone spread over 10 Acers of land with a capacity to process 3,00,000 Metric Tons at our latest bhular plant with state of the art sortex machine from sortex U.K. Another warehouse facility is also under construction at our Punjab facility on 12 Acre of land at FIEDMC Faisalabad to cater the Basmati buyers.

Exports During 2019 – 2020: INB has a turnover of Pak RS 8 billion during the year 2019~2020 with export value of 1, 25,000 Metric Ton.

UNIT 1: INB Rice Mill PORT QASIM is spread on 10 Acres of land with warehouse of over 200,000 sq feet, with production capacity of 20 Tons per hour which comes to 175000 metric tons per year which is being converted into 40 Tons per hour in next 6 month which comes to 350000 metric tons per year. Our new mill is also equipped with the state of art machinery imported from BUHLER, Germany comprising cleaner, de-stoners, and set of polishers to ensure homogeneous whiteness on rice up to 46 Kett along with the 7 most modern color sorter machines from sortex. The plant is strictly according to ISO-9001:2008 standards and H.A.C.C.P. standards.

UNIT 2: INB Rice Mill S.I.T.E is equipped with the state of art machinery imported from BUHLER, Germany comprising cleaner, de-stoners, and set of polishers to ensure homogeneous whiteness on rice up to 46 Kett along with the 3 most modern color sorter machines from sortex. INB has its own Power Generation, having capacity to process 1,25,000 metric tons rice per year. The plant is strictly according to ISO-9001:2008 standards and H.A.C.C.P. standards.

UNIT 3: INB FIEDMC spread over of 12.5 Acre of land with state of the art storage facility inb certified Punjab is also under construction to capture Brown Basmati Rice market for Europe and will also have parboiled and steaming facilities.

INB DUBAI OFFICE: In order to have a strong market presence in the Gulf region, Irfan Noman Brothers (Pvt.) Ltd. have established a marketing office and warehouse right in the heart of Dubai, UAE. In 2007, we identified the gap in the Middle Eastern rice market and opened our shop in Dubai where ready stocks are always available to cater the immediate demands of the customers in UAE.

Canada Office: INB Canada Office look after North America Market & look after our famous Mehman Brand sales in North American Territories for last 5 years.

Mehman Outlets:  INB also had its own outlets in different places of city to sell our Premium Brand of Basmati Rice in domestic markets for last 15 years.

Brand of the year Award:  Our famous brand “Mehman” is also the recipient of best brand of the year award from prime minister of Pakistan.

Certification:H.A.C.C.P certification of UK, ISO-9001:2008 certified from UK, HALAL Certified Company, Also in process of G.M.P Certification

VISION: We, at Irfan Noman Brothers (Pvt.) Ltd., being one of the top exporters of rice from Pakistan aspire to carve a niche for ourselves in the rice industry by becoming international market leaders and also by providing our customers with the best quality product.

MISSION: Dedicated to positioning our brand internationally, this adheres to high quality standards whilst providing superior products and services to our valuable customers.

Источник: https://www.inbrice.com/about-us/
24 hours Banking - IDBI Bank Internet Banking

With the rapid inb certified that is happening around and with Internet becoming an essential part of our routine lives, Banking on Internet Platform assumes a special significance. IDBI Bank provides its customers, 24 hours online banking services - anytime, anywhere with its Internet Banking.

Now, your bank has a new address. Perform all your banking transactions like Account Information, Demat Account Information, Online instructions, Requests, Bill payments and other merchant payments, from the comfort of your home or office.

Agreeably, such a service requires security of the highest nature and complete privacy protection. Thus, we provide a completely secure environment, using 128-bit encryption SSL (Secure Sockets Layer), digitally certified by VeriSign. 128-bit SSL ensures world-class security for Internet and e-commerce transactions.

Account Information:

  • Account balance
  • Account related enquiries and status
  • Transaction tracking and history
  • Loan Installments and funds flow details
  • Statements
  • Cheque status

Demat Account Information:

  • Demat Account Details displays the name, correspondence address, account numbers and bank account numbers associated with the account.
  • Holding Statements displays the list of demat scrip with ISIN code, scrip name, and balance.
  • Statement of Transaction lists the transactions for a period, with details of security and balances.
  • Billing statement details the charges for respective transactions.

Online Instructions and Requests:

  • Cheque book
  • Stop payment
  • Fixed and Recurring deposit opening / renewal
  • Mobile / DTH recharge
  • IPO application through ASBA

Online Payment Services:

Internet Banking offers online payment facility linked with merchant websites/e-shops through its direct debit payment gateway service. The Bank offers this facility to online merchants/service providers requiring online payment services such as e-commerce merchants, Online Share Trading portals, an AMC selling Online Mutual Funds etc.

Bill Payment and Presentment:

EBPP - Electronic Bill Presentment and Payment feature allows IDBI Bank customers to pay for their utility bills online through the Bank's Internet Banking service or also by visiting the website of the service provider.



How To Apply

Get a Internet Banking in 3 easy steps.

01. Get In Touch

Call on our Phone Banking numbers Toll Free -
1800-209-4324
1800-22-1070 (24x7 service)

03. Receive a Call Back

Our representative will contact you at the earliest.

Get In Touch

Источник: https://www.idbibank.in/idbi-bank-internet-banking.aspx

     

Exhibit 10.1

SEPARATION AND DISTRIBUTION AGREEMENT

THIS SEPARATION AND DISTRIBUTION AGREEMENT (this “Agreement”) is entered into as of November 14, 2007, between Integrated BioPharma, Inc., a Delaware corporation (“INB”), and InB:Biotechnologies, Inc., a New Jersey corporation (“Biotech”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in Article 6 hereof.

RECITALS

WHEREAS, INB currently owns a majority of the issued and outstanding common stock of Biotech;

WHEREAS, Biotech is engaged in the specialty pharmaceutical business and related businesses as described in the Information Statement that is an exhibit to the Form 10 to be filed by Biotech with the Securities and Exchange Commission (the “Biotech Business”);

WHEREAS, the Boards of Director of INB has determined that it would be appropriate and desirable for INB to distribute, pro rata, to the holders of its common stock, all of the shares of Biotech common stock owned by INB (the “Distribution”);

WHEREAS, subsequent to the Distribution, and as provided for in this Agreement, Biotech will be an independent public company (the “Separation”); and

WHEREAS, INB and Biotech intend that the Separation and the Distribution will qualify as a tax-free reorganization under Section 355 of the Internal Revenue Code of 1986, as amended (the “Code”).

NOW, THEREFORE, in consideration of the foregoing and the covenants and agreements set forth below, the parties hereto agree as follows:

1.     SEPARATION

1.1.     Distribution Date. Unless otherwise provided in this Agreement, or in any agreement to be executed in connection with this Agreement, the effective time and date of the Distribution, and each undertaking or agreement in connection therewith shall be such date as may be fixed by the Board of Directors of INB following satisfaction of the conditions to the Distribution set forth in Section 3.9 (the “Distribution Date”).


1


1.2.     Closing of Transactions. Unless otherwise provided herein, the closing of the transactions contemplated in Article 2 shall occur on the Distribution Date. Executed copies of each of the Ancillary Agreements and any other agreements or documents executed in connection with the transaction contemplated hereby, or thereby, shall be held in escrow by Greenberg Traurig, LLP (the “Escrow Agent”) for delivery as provided in Section 1.3.

1.3.     Exchange of Secretary’s Certificates. Upon receipt of a certificate of the Secretary or an Assistant Secretary of INB in form satisfactory to the Escrow Agent, the Escrow Agent shall deliver to Biotech on behalf of INB all of the items required to be delivered by INB hereunder pursuant to Section 2.1 and each such item shall be deemed to be delivered to Biotech as of the Distribution Date upon delivery of such certificate. Upon receipt of a certificate of the Secretary or an Assistant Secretary of Biotech in form satisfactory to the Escrow Agent, the Escrow Agent shall deliver to INB on behalf of Biotech all of the items required to be delivered by Biotech pursuant to Section 2.2 hereunder and each such item shall be deemed to be delivered to INB as of the Distribution Date upon receipt of such certificate.  

2.     DOCUMENTS TO BE DELIVERED ON THE DISTRIBUTION DATE  

2.1.     Documents to Be Delivered by INB. On the Distribution Date or such other date as may be established by the board of directors of INB, or as otherwise agreed by the parties, INB will deliver to Biotech all of the following items and agreements, in each case in form and substance customary for a transaction structured like the Distribution and as mutually agreed upon by INB and Biotech (collectively, together with all agreements and documents contemplated by such agreements, the “Ancillary Agreements”):

(a)     A duly executed Tax Sharing Agreement, in the form attached hereto as Exhibit 1;

(b)     A duly executed Transitional Services Agreement, in the form attached hereto as Exhibit 2;

(c)     A duly executed Confidentiality and Nondisclosure Agreement, in the form attached hereto as Exhibit 3;

(d)     A duly executed Indemnification and Insurance Matters Agreement, in the form attached hereto as Exhibit 4;

(e)     Such other agreements, documents or instruments as the parties may agree are necessary or desirable in order to achieve the purposes hereof.


2


2.2.     Documents to Be Delivered by Biotech. As of the Distribution Date, Biotech will deliver to INB each of the Ancillary Agreements.

3.     THE DISTRIBUTION

3.1.     Delivery of Shares for Distribution. On or prior to the Distribution Date, INB will deliver to the distribution agent for the Distribution (the “Distribution Agent”) and the INB transfer agent, a single stock certificate, endorsed by INB, representing all of the outstanding shares of common stock of Biotech then owned by INB. The shares of Biotech common stock represented by said certificate shall be the shares distributed to the stockholders of INB, pursuant to the Distribution. INB shall cause the Distribution Agent to distribute on the Distribution Date the appropriate number of such shares of common stock of Biotech to each shareholder of INB as of the record date of the Distribution to be set by INB, or the designated transferee or transferees of such shareholder. 

3.2.     Shares Received. Subject to Sections 4.4 and 4.5, each holder of common stock of INB on the Record Date (or such holder’s designated transferee or transferees) will be entitled to receive in the Distribution a number of shares of common stock of Biotech equal to the number of shares of common stock of INB held by such holder on the Record Date. The amount of shares issued and outstanding to the individual shareholders of Biotech holding such shares prior to the Distribution Date shall not be increased or reduced by the Distribution.

3.3.     Obligation to Provide Information. Biotech and INB, as the case may be, will provide to the Distribution Agent all share certificates and any information required in order to complete the Distribution on the basis specified above.

3.4.     Information Statement. Prior to the Distribution Date, INB and Biotech shall prepare and mail, to the holders of common stock of INB such information concerning Biotech and the Distribution and such other matters as INB shall reasonably determine are necessary and as may be required by law. INB and Biotech will prepare, and Biotech will, to the extent required under applicable law, file with the Securities and Exchange Commission any such documentation that INB and Biotech determine is necessary or desirable to effectuate the Distribution, and INB and Biotech shall each use its reasonable commercial efforts to obtain all necessary approvals from the Commission with respect thereto as soon inb certified practicable.

3.5.     Blue Sky. INB and Biotech shall take all such actions as may be necessary or appropriate under the securities or blue sky laws of the United States (and any comparable laws under any foreign jurisdiction) in connection with the Distribution.


3


3.6.     Nasdaq Listing. Biotech shall prepare and file, and shall use its reasonable commercial efforts to have approved, an application for the additional listing of the common stock of Biotech to be distributed in the Distribution on the Nasdaq Capital Market, or such other national stock exchange as determined by Biotech’s Board of Directors, subject to official notice of distribution.

3.7.     Conditions. INB and Biotech shall take all reasonable steps necessary and appropriate to cause the conditions set forth in Section 3.9 to be satisfied and to effect the Distribution on the Distribution Date. 

3.8.     Sole Discretion of INB. INB agrees to use commercially reasonable efforts to complete the Distribution on or before February 1, 2008. INB shall, in its sole and absolute discretion, determine the date of the consummation of the Distribution and all terms of the Distribution, including, without limitation, the form, structure and terms of any transaction(s) and/or offering(s) to effect the Distribution and the timing of and conditions to the consummation of the Distribution. In addition, INB may at any time and from time to time until the completion of the Distribution, modify or change the terms of the Distribution, including, without limitation, by accelerating or delaying the timing of the consummation of all or part of the Distribution. Biotech shall cooperate with INB in all respects to accomplish the Distribution and shall, at INB’s direction, promptly take any and all actions necessary or desirable to effect the Distribution. INB shall select any financial printer, distribution agent and outside counsel for INB; provided, however, that nothing herein shall prohibit Biotech from engaging (at its own expense) its own financial, legal, accounting and other advisors in connection with the Distribution.

3.9.     Conditions Precedent to Distribution. The following are conditions that must take place prior to the consummation of the Distribution. The conditions are for the sole benefit of INB and shall not give rise to or create any duty on the part of INB or the INB Board of Directors to waive or not waive any such condition.

(a)     Form 10. The Form 10 to be filed by Biotech shall be effective under the Exchange Act, with no stop order in effect with respect thereto.

(b)      Tax Opinion. INB shall have obtained an opinion letter from Greenberg Traurig, LLP in form and substance satisfactory to INB (in its sole discretion), and such letter shall remain in effect as of the Distribution Date, to the effect that the distribution by INB of all of its Biotech stock to the stockholders of INB should qualify as a tax free transaction under Section 355 of the Code.


4


(c)     Government Approvals. Any material governmental approvals and consents necessary to consummate the Distribution, including without limit a declaration by the SEC of the effectiveness of the registration of the Biotech common stock on Form 10, shall have been obtained and be in full force and effect.

(d)     Listing of BiotechStock. Biotech shall have received the approval by Nasdaq or a national stock exchange for the listing of the Biotech common stock on the Nasdaq Capital Market, or national stock exchange.

(e)     No Legal Restraints. No order, injunction or decree issued by any court or agency of competent jurisdiction or other legal restraint or prohibition preventing the consummation of the Distribution shall be in effect and no other event outside the control of INB shall have occurred or failed to occur that prevents the consummation of the Distribution.

(f)     No Material Adverse Effect. No events or developments other than the Distribution itself shall have occurred subsequent to the Record Date that, in the judgment of the Board of Directors of INB, would result in the Distribution having a material adverse effect on INB or on the stockholders of INB.

(g)     Ancillary Agreements. Each Ancillary Agreement shall be duly executed and delivered and be in full force and effect.

(h)     Conversion of Debt to Equity. Simultaneous with the Distribution, Biotech shall have converted a portion of the debt owed to INB into equity of Biotech, such that INB shall hold shares of Common Stock of Biotech representing 6% of the issued and outstanding shares of Biotech Common Stock subsequent to the distribution.

4.     COVENANTS AND OTHER MATTERS

4.1.     Required Consent. To preserve the tax free character of the Distribution, for the two years immediately following the effective date of the Distribution Date, Biotech may not issue any additional shares of its common stock in excess of the shares issued with respect to the Distribution, nor enter into any agreement, arrangement or understanding with any Person that contemplates a transaction, which would, singly or in combination with any other issuance or transaction, result in a change in 50% or more of the direct or indirect ownership of the Biotech common stock from said ownership as constituted on the Distribution Date. If the Biotech Board of Directors, by a written vote or unanimous consent, determine that such issuance or transaction is in the best interest of the Biotech shareholders, the Chairman of Biotech may submit a request for the consent of the INB Board to effect such issuance or enter into such transaction. Such request shall be in writing, addressed to the Chairman inb certified the INB Board of Directors, setting forth the details of the proposed issuance or transaction, the benefits accruing to the Biotech shareholders in connection therewith, and such assurances and security regarding the possible tax


5


liability that could be engendered by the proposed issuance or transaction. The INB Board may, in its sole and absolute discretion, by resolution at a meeting duly called and held or by unanimous written consent, consent to or elect to withhold their consent to such proposed issuance or transaction. The requirement under this Section 4.1 to obtain the consent of the INB Board to any proposed issuance or transaction shall cease on the second anniversary of the Distribution, and shall thereafter be of no further force or effect.

4.2.     Other Agreements. INB and Biotech agree to execute or cause to be executed by the appropriate parties and deliver, as appropriate, such other agreements, instruments and other documents as may be necessary or desirable in order to effect the purposes of this Agreement and the Ancillary Agreements.

4.3.     Additional Transitional Services Agreements. INB and Biotech will enter into the Transitional Services Agreement covering the provision of various transitional services by INB for Biotech, including SEC reporting, internal auditing and financial, accounting, legal, real estate and such other services Biotech may wish to obtain from INB. Such services will generally be provided for a fee that will be approximately equal to the direct costs and indirect costs of providing such services plus five percent (5.0%). The transitional services agreement will generally provide for a term of three years, or less.

4.4.     Agreement for Exchange of Information.

(a)     Generally.


6


(b)     Internal Accounting Controls; Financial Information. After the Distribution Date, (i) each party shall maintain in effect at its own cost and expense adequate systems and controls for its business to the extent necessary to enable the other party to satisfy its reporting, accounting, audit and other obligations, and (ii) each party shall provide, or cause to be provided, to the other party and its Subsidiaries in such form as such requesting party shall request, at no charge to the requesting party, all financial and other data and information as the requesting party determines necessary or advisable in order to prepare its financial statements and reports or filings with any Governmental Authority.

(c)     Ownership of Information. Any Information owned by a party that is provided to a requesting party pursuant to this Section 4.4 shall be deemed to remain the property of the providing party. Unless specifically set forth herein, nothing contained in this Agreement shall be construed as granting or conferring rights of license or otherwise in any such Information.

(d)     Record Retention. To facilitate the possible exchange of Information pursuant to this Section 4.4 and other provisions of this Agreement after the Distribution Date, each party agrees to use its reasonable commercial efforts to retain all Information in its respective possession or control on the Distribution Date substantially in accordance with the policies of INB as in effect on the Distribution Date. However, except as set forth in the Tax Sharing Agreement, at any time after the Distribution Date, each party may amend its respective record retention policies at such party’s discretion; provided, however, that if a party desires to effect the amendment within three (3) years after the Distribution Date, the amending party must give thirty (30) days prior written notice of such change in the policy to the other party to this Agreement. No party will destroy, or permit any of its Subsidiaries to destroy, any Information that exists on the Distribution Date (other than Information that is permitted to be destroyed under the current record retention policies of INB) and that falls under the categories listed in Section 4.4(a), without first using its reasonable commercial efforts to notify the other party of the proposed destruction and giving the other party the opportunity to take possession of such Information prior to such destruction.

(e)     Limitation of Liability. No party shall have any liability to any other party in the event that any Information exchanged or provided pursuant to this Section 4.4 is found to be inaccurate, in the absence of gross negligence or willful misconduct by the party providing such Information. No party shall have any liability to any other party if any Information is destroyed or lost after reasonable commercial efforts by such party to comply with the provisions of Section 4.4(d).

(f)     Other Agreements Providing for Exchange of Information. The rights and obligations granted under this Section 4.4 are subject to any specific limitations, qualifications or additional provisions on the sharing, exchange or confidential treatment of Information set forth in this Agreement and any Ancillary Agreement.


7


(g)     Production of Witnesses; Records; Cooperation. After the Distribution Date, except in the case of a legal or other proceeding by one party against another party (which shall be governed by such discovery rules as may be applicable under Section 4.9 or otherwise), each party hereto shall use its reasonable commercial efforts to make available to each other party, upon written request, the former, current and future directors, officers, employees, other personnel and agents of such party as witnesses and any books, records or other documents within its control or which it otherwise has the ability to make available, to the extent that any such person (giving consideration to business demands of such directors, officers, employees, other personnel and agents) or books, records or other documents may reasonably be required in connection with any legal, administrative or other proceeding in which the requesting party may from time to time be involved, regardless of whether such legal, administrative or other proceeding is a matter with respect to which indemnification may be sought hereunder. The requesting party shall bear all costs and expenses in connection therewith.

4.5.     Auditors and Audits; Annual and Quarterly Statements and Accounting. Each party agrees that, for so long as INB under generally accepted accounting principles to consolidate Biotech’s results of operations and financial position within INB’s financial statements:

(a)     Selection of Auditors. Biotech shall not select a different firm of independent certified public accountants that is used by INB to serve as its (and its Subsidiaries’) independent auditors (“Biotech’s Auditors”) for purposes of providing an opinion on its consolidated financial statements without INB’s prior written consent (which shall not be unreasonably withheld, delayed or conditioned).

(b)     Date of Auditors’ Opinion and Quarterly Reviews. Biotech shall use its reasonable commercial efforts to enable the Biotech Auditors to complete their audit such that they will date their opinion on Biotech’s audited annual financial statements on the same date that INB’s independent auditors (“INB’s Auditors”) date their opinion on INB’s audited annual financial statement, and to enable INB to meet its timetable for the printing, filing and public dissemination of INB’s annual financial statements for so long as INB is a publicly traded company. Biotech shall use its reasonable commercial efforts to enable the Biotech Auditors to complete their quarterly review procedures such that they will provide clearance on Biotech’s quarterly financial statements on the same date that INB’s Auditors provide clearance on INB’s quarterly financial statements.


8


(c)     Annual and Quarterly Financial Statements. Biotech shall provide to INB on a timely basis all Information that INB reasonably requires to meet its schedule for the preparation, printing, filing, and public dissemination of INB’s annual and quarterly financial statements for so long as INB is a publicly traded company. Without limiting the generality of the foregoing, Biotech will provide all required financial Information with respect to Biotech and its Subsidiaries to Biotech’s Auditors in a sufficient and reasonable time and in sufficient detail to permit Biotech’s Auditors to take all steps and perform all reviews necessary to provide sufficient assistance to INB’s Auditors with respect to financial Information to be included or contained in INB’s annual and quarterly financial statements. Similarly, INB shall provide to Biotech on a timely basis all financial Information that Biotech reasonably requires to meet its schedule for the preparation, printing, filing, and public dissemination of Biotech’s annual and quarterly financial statements. Without limiting the generality of the foregoing, INB will provide all required financial Information with respect to INB and its Subsidiaries to INB’s Auditors in a sufficient and reasonable time and in sufficient detail to permit INB’s Auditors to take all steps and perform all reviews necessary to provide sufficient assistance to Biotech’s Auditors with respect to Information to be included or contained in Biotech’s annual land for sale boone county mo quarterly financial statements.

(d)     Identity of Personnel Performing the Annual Audit and Quarterly Reviews. Biotech shall authorize Biotech’s Auditors to make available to INB’s Auditors both the personnel who performed or will perform the annual audits and quarterly reviews of Biotech and work papers related to the annual audits and quarterly reviews of Biotech, in all cases within a reasonable time prior to Biotech’s Auditors’ opinion date, so that INB’s Auditors are able to perform the procedures they consider necessary to take responsibility for the work of Biotech’s Auditors as it relates to INB’s Auditors’ report on INB’s financial statements, all within sufficient time to enable INB to meet its timetable for the printing, filing and public dissemination of INB’s annual and quarterly statements. Similarly, INB shall authorize INB’s Auditors to make available to Biotech’s Auditors both the personnel who performed or will perform the annual audits and quarterly reviews of INB and work papers related to the annual audits and quarterly reviews of INB, in all cases within a reasonable time prior to INB’s Auditors’ opinion date, so that Biotech’s Auditors are able to perform the procedures they consider necessary to take responsibility for the work of INB’s Auditors as it relates to Biotech’s Auditors’ report on Biotech’s statements, all within sufficient time to enable Biotech to meet its timetable for the printing, filing and public dissemination of Biotech’s annual and quarterly financial statements.


9


(e)     Access to Books and Records. Biotech shall provide INB’s internal auditors and their designees access to Biotech’s and its Subsidiaries’ books and records so that INB may conduct reasonable audits relating to the financial statements provided by Biotech pursuant hereto as well as to the internal accounting controls and operations of Biotech and its Subsidiaries. Similarly, INB shall provide Biotech’s internal auditors and their designees access to INB’s and its Subsidiaries’ books and records so that Biotech may conduct reasonable audits relating to the financial statements provided by INB pursuant hereto as well as to the internal accounting controls and operations of INB and its Subsidiaries

(f)     Notice of Change in Accounting Principles. Biotech shall give INB as much prior notice as reasonably practical of any proposed determination of, or any significant changes in, its accounting estimates or accounting principles from those in effect on the Distribution Date. Biotech will consult with INB and, if requested by INB, Biotech will consult with INB’s Auditors with respect thereto. INB shall give Biotech as much prior notice as reasonably practical of any proposed determination of, or any significant changes in, its accounting estimates or accounting principles from those in effect on the Distribution Date.

(g)     Conflict with Third-Party Agreements. Nothing in Sections 4.4 and how to get a new debit card bank of america shall require Biotech to violate any agreement with any third party regarding the confidentiality of confidential and proprietary information relating to that third party or its business; provided, however, that in the event that Biotech is required under Sections 4.4 and 4.5 to disclose any such Information, Biotech shall use all commercially reasonable efforts to seek to obtain such third party’s consent to the disclosure of such information.

4.6.     Consistency with Past Practices. At all times, INB and Biotech will conduct the Biotech Business before the Distribution Date in the ordinary course, consistent with past practices.

4.7.     Payment of Expenses. Except as otherwise provided in this Agreement, the Ancillary Agreements or any other agreement between the parties relating to the Distribution, all costs and expenses of the parties hereto in connection with the Distribution shall be borne and paid by INB. Biotech and INB shall each be responsible for their own internal fees, costs and expenses incurred in connection with the Distribution.

4.8.     Governmental Approvals. To the extent that the Distribution requires any Governmental Approvals, the parties will use their reasonable commercial efforts to obtain any such Governmental Approvals.


10


4.9.     Dispute Resolution

(a)     Mediation. With respect to any dispute, claim or controversy between the parties arising out of or relating to this Agreement or any Ancillary Agreement, the parties agree that they will attempt in good faith to resolve the matter through negotiation. Upon mutual agreement of the parties, the matter may be submitted to any mutually agreed-upon mediation service for mediation. Mediation shall be commenced by providing to the mediation service a joint, written request for mediation, setting forth the subject of the dispute and the relief requested. The parties will cooperate with the mediation service and with one another in selecting a neutral mediator and inb certified scheduling the mediation proceedings. The parties covenant that they will use commercially reasonable efforts in participating in the mediation. The parties agree that the mediator’s fees and expenses and the costs incidental to the mediation will be shared equally between the parties. The parties further agree that all offers, promises, conduct and statements, whether oral or written, made in the course of the mediation by any of the parties, their agents, employees, experts and attorneys, and by the mediator and any employees of the mediation service, are confidential, privileged and inadmissible for any purpose, including impeachment, in any litigation or other proceeding involving the parties, provided that evidence that is otherwise admissible or discoverable shall not be rendered inadmissible or non-discoverable as a result of its use in the mediation. Either party may commence an arbitration proceeding in accordance with Section 4.9(b) with respect to the matter submitted to mediation at any time after the completion of the initial mediation session, or ninety (90) days after the date of filing the written request for mediation, whichever occurs first.

(b)     Arbitration. Upon the prior written notice provided by to the other party pursuant to Section 4.9(a), any claim arising out of or related to this Agreement or any Ancillary Agreement, or the default hereof or thereof, which has not been resolved by mediation shall be settled by arbitration, which shall be conducted at in accordance with the rules of the American Arbitration Association then in effect, as modified or supplemented herein, or as the parties mutually agree otherwise. The decision of the arbitrator


11


shall be final, and judgment may be entered upon it in accordance with the applicable law in any court having jurisdiction. Any claim for relief made pursuant to this Agreement shall be made within one (1) year from the date upon which the party claiming relief knew or should have known of the cause of action constituting such claim. The arbitrator or arbitrators may award monetary damages to the prevailing party only for actual damages, but may not award punitive, consequential, special or incidental damages as between the parties. Notwithstanding the above, punitive, consequential special or incidental damages may be awarded if such damages are payable to a third party.

5.     MISCELLANEOUS

5.1.     Limitation of Liability. In no event shall INB, its subsidiaries, and any of their respective officers, directors, employees or agents, or Biotech, its subsidiaries, and any of their respective officers, directors, employees or agents be liable to any other member of INB or Biotech for any special, consequential, indirect, incidental or punitive damages or lost profits, however caused and on any theory of liability (including negligence) arising in any way out of this agreement, whether or not such party has been advised of the possibility of such damages; provided, however, that the foregoing limitations shall not limit each party’s indemnification obligations for liabilities as set forth in the Indemnification and Insurance Matters Agreement.

5.2.     Entire Agreement. This Agreement, the Ancillary Agreements and the Exhibits and Schedules referenced or attached hereto and thereto, constitute the entire agreement between the parties with respect to the subject matter hereof and thereof and shall supersede all prior written and oral and all contemporaneous oral agreements and understandings with respect to the subject matter hereof and thereof.

5.3.     Governing Law. This Agreement shall be construed in accordance with and all Disputes hereunder shall be governed by the laws of the State of Delaware, excluding its conflict of law rules.

5.4.     Termination. This Agreement and all Ancillary Agreements may be terminated and the Distribution abandoned at any time prior to the Distribution Date by and in the sole discretion of INB without the approval of Biotech. In the event of termination pursuant to this Section 5.4, no party shall have any liability of any kind to the other party.


12


5.5.     Notices. Notices, offers, requests or other communications required or permitted to be given by either party pursuant to the terms of this Agreement shall be given in writing to the respective parties to the following addresses:

if to INB :

Integrated BioPharma, Inc.
225 Long Avenue
Hillside, New Jersey 07205

Attention: President

if to Biotech:

InB:Biotechnologies, Inc.

9 Innovation Way, Suite 100

Newark, Delaware 19711

Attention: President

or to such other address as the party to whom notice is given may have previously furnished to the other in writing as provided herein. Any notice involving non-performance, termination, or renewal shall be sent by hand delivery, recognized overnight courier or, within the United States, may also be sent via certified mail, return receipt requested. All other notices may also be sent by fax, confirmed by first class mail. All notices shall be deemed to have been given and received on the earlier of actual delivery or three (3) days from the date of postmark.

5.6.     Counterparts. This Agreement, including the Ancillary Agreements and the Exhibits and Schedules thereto and the other documents referred to herein or therein, may be executed in counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same agreement.

5.7.     Binding Effect; Assignment. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective legal representatives and successors, and nothing in this Agreement, express or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever under or by reason of this Agreement. This Agreement may be enforced separately by INB and Biotech. Neither party may assign this Agreement or any rights or obligations hereunder, without the prior written consent of the other party, and any such assignment shall be void; provided, however, either party may assign this Agreement to a successor entity in conjunction with such party’s reincorporation.


13


5.8.     Severability. If any term or other provision of this Agreement or the Exhibits or Schedules attached hereto is determined by a court, administrative agency or arbitrator to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to either party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that transactions contemplated hereby are fulfilled to the fullest extent possible.

5.9.     Failure or Indulgence Not Waiver; Remedies Cumulative. No failure or delay on the part of either party hereto in the exercise of any right hereunder shall impair such right or be construed to be a waiver of, or acquiescence in, any breach of any representation, warranty or agreement herein, nor shall any single or partial exercise of any such right preclude other or further exercise thereof or of any other right. All rights and remedies existing under this Agreement or the Exhibits or Schedules attached hereto are cumulative to, and not exclusive of, any rights or remedies otherwise available.

5.10.     Amendment. No change or amendment will be made to this Agreement or the Exhibits or Schedules attached hereto except by an instrument in writing signed on behalf of each of the parties to such agreement.

5.11.     Authority. Each of the parties hereto represents to the other that (a) it has the corporate or other requisite power and authority to execute, deliver and perform this Agreement, (b) the execution, delivery and performance of this Agreement by it have been duly authorized by all necessary corporate or other actions, (c) it has duly and validly executed and delivered this Agreement, and (d) this Agreement is a legal, valid and binding obligation, enforceable against it in accordance with its terms subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and general equity principles.

5.12.     Interpretation. The headings contained in this Agreement, in any Exhibit or Schedule hereto and in the table of contents to this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Any capitalized term used in any Exhibit or Schedule but not otherwise defined therein, shall have the meaning assigned to such term in this Agreement. When a reference is made in this Agreement to an Article or a Section, Exhibit or Schedule, such reference shall be to an Article or Section of, or an Exhibit or Schedule to, this Agreement unless otherwise indicated.


14


5.13.     Conflicting Agreements. In the event of conflict between this Agreement and any Ancillary Agreement or other agreement executed in connection herewith, the provisions of such other agreement shall prevail.

5.14     Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person; provided, however, that any investor acquiring shares of Common Stock of Biotech prior to the Distribution Date shall be an intended beneficiary of this Agreement.

6.     DEFINITIONS

6.1.     Biotech. “Biotech” means Biotech, each subsidiary of Biotech as of the date of this Agreement and as of the Distribution Date, and any time thereafter the Distribution Date, and each Person that becomes a Subsidiary of Biotech after the Distribution Date.

6.2.     Biotech’s Auditors. “Biotech’s Auditors” means Biotech’s independent certified public accountants.

6.3.     Distribution Date. “Distribution Date” has the meaning set forth in the Section 1.1 hereof.

6.4.     Governmental Approvals. “Governmental Approvals” means any notices, reports or other filings to be made, or any consents, registrations, approvals, permits or authorizations to be obtained from, any Governmental Authority.

6.5.     Governmental Authority. “Governmental Authority” shall mean any federal, state, local, foreign or international court, government, department, commission, board, bureau, agency, official or other regulatory, administrative or governmental authority.

6.6.     INB. “INB” means INB, each subsidiary of INB (other than Biotech) as of the date of this Agreement and from and after the Distribution Date, and each Person that becomes a Subsidiary of INB after the Distribution Date.

6.7     INB’s Auditors. “INB’s Auditors” means INB’s independent certified public accountants.


15


6.8.     Information. “Information” means information, whether or not patentable or copyrightable, in written, oral, electronic or other tangible or intangible forms, stored in any medium, including studies, reports, records, books, contracts, instruments, surveys, discoveries, ideas, concepts, know-how, techniques, designs, specifications, drawings, blueprints, diagrams, models, prototypes, samples, flow charts, data, computer data, disks, diskettes, tapes, computer programs or other software, marketing plans, customer names, communications by or to attorneys (including attorney-client privileged communications), memos and other materials prepared by attorneys or under their direction (including attorney work product), and other technical, financial, employee or business information or data.

6.9.     Person. “Person” means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.

6.10.     Record Date. “Record Date” means the record date for the Distribution to be set by the INB Board of Directors.

6.11.     Subsidiary. “Subsidiary” of any Person means a corporation or other business organization whether incorporated or unincorporated of which at least a majority of the securities or interests having by the terms thereof ordinary voting power to elect at least a majority of the board of directors or others performing similar functions with respect to such corporation or other organization is directly or indirectly owned or controlled by such Person or by any one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries; provided, however, that no Person that is not directly or indirectly wholly-owned by any other Person shall be a Subsidiary of such other Person unless such other Person controls, or has the right, power or ability to control, that Person.


16


WHEREFORE, the parties have signed this Separation and Distribution Agreement effective as of the date first set forth above.

INTEGRATED BIOPHARMA, INC.



INB:BIOTECHNOLOGIES, INC.


17

Источник: https://ir.ibioinc.com/sec-filings/content/0001420720-08-000003/exhibit10_1.htm

Inb certified -

Cisco ACI In-Band Management Configuration for Hardware Flow Telemetry Export

Step 1

Configure the VLAN pool.

  1. Navigate to the Create VLAN Pool page:

    , then right-click and choose Create VLAN Pool.

  2. On the Create VLAN Pool page, perform the following actions:

    1. Enter a name for the VLAN pool.

    2. (Optional) Enter a description for the VLAN pool.

    3. In the Allocation Mode field, select Static Allocation.

      This is typically used when the pool will be referenced from a static source, such as a static path binding for an EPG for use with new-deployment servers.

    4. Click Add (+) in the Encap Blocks area to add an encapsulation block.

      The encapsulation blocks define the range of VLANs in the VLAN pool.

    5. On the Create Ranges page, enter the following information:

      • Range: Enter a value in this field. For this use case, we would enter 11 in this field.

      • Allocation Mode: Choose Static Allocation.

      • Role: Choose External or On the wire encapsulations.

      Then click OK to save the values entered on the Create Ranges page.

  3. On the Create VLAN Pool page, click Submit to save the values entered on this page.

Step 2

Configure the physical domain and AEP.

  1. Navigate to the Create Physical Domain page:

    , then right-click and choose Create Physical Domain.

  2. On the Create Physical Domain page, perform the following actions:

    1. Enter a name for the physical domain.

    2. In the Associated Attachable Entity Profile field, select the AEP that is used for APIC connectivity.

      This could be the default AEP or some other AEP. Select the AEP that is used for APIC connectivity so that you are deploying the management EPG for the APIC in-band management interface.

    3. In the VLAN Pool field, choose the VLAN pool that you configured in the previous step.

    4. Click Submit to save the values entered on this page.

Step 3

Apply the access policy to the interface connecting to the Cisco APIC.

  1. Create a leaf access port policy group by navigating to the Create Leaf Access Port Policy Group page:

    , then right-click and choose Create Leaf Access Port Policy Group.

  2. Enter a name for the leaf access port policy group, then, in the Attached Entity Profile field, choose the AEP that has the domain with the VLAN pool for the in-band management, and then click Submit.

  3. Create a leaf interface policy by navigating to the Create Leaf Interface Profile page:

    , then right-click and choose Create Leaf Interface Profile.

  4. Enter a name for the leaf interface profile, then click Add (+) in the Interface Selectors area.

  5. In the Create Access Port Selector page, enter the necessary information, then, in the Interface Policy Group field, choose the leaf access port policy group you created in the previous steps.

  6. Click OK to complete the configuration in the Create Access Port Selector page, then click Submit to complete the configuration in the Create Leaf Interface Profile page.

  7. Create a leaf profile by navigating to the Create Leaf Profile page:

    , then right-click and choose Create Leaf Profile.

  8. On the Create Leaf Profile page, enter the necessary information:

    • In the Leaf Selectors area, select the necessary leaf switches and configure the switch selector information for those leaf switches.

    • In the Interface Selector Profiles area, choose the leaf interface profile that you created in the previous set of steps.

  9. Click Finish in the Create Leaf Profile page.

Step 4

Configure the in-band management EPG.

  1. Navigate to the Create In-Band Management EPG page:

    , then right-click and choose Create In-Band Management EPG.

  2. Enter the necessary information on the Create In-Band Management EPG page, specifically these fields:

    • Name: Leave default as the name for the in-band management EPG.

    • Encap: Enter the access encapsulation. For example, for this use case, you would enter vlan-11 to match the information that you entered in Step 1.b.

    • Bridge Domain: The inb bridge domain under the mgmt tenant.

      This inb bridge domain is the bridge domain that was mentioned in the Required inb VRF Under mgmt Tenant section earlier in this document. Technically, this could be a different bridge domain, as long as it is in the mgmt VRF.

  3. Click Submit.

    Click the new in-band management EPG to be displayed under the Node Management EPGs area in the left navigation tree and verify that no fault is displayed for the new EPG.

Step 5

Assign in-band management IP addresses to the leaf and spine switches.

  1. Navigate to the Create Node Management Addresses page:

    , then right-click and choose Create Node Management Addresses.

  2. Enter the necessary info on the Create Node Management Addresses page:

    1. In the Select Nodes By field, choose Specific.

    2. In the Nodes area, select the specific nodes for the leaf and spine switches.

    3. In the Config area, choose In-Band Addresses.

    4. In the In-Band Management EPG field, select the default in-band management EPG that you configured in the previous step.

    5. In the In-Band Gateway and In-Band IP Addresses fields, set the in-band gateway and IP address range for the switches.

  3. Click Submit.

Step 6

Assign in-band management IP addresses to the APICs.

  1. Navigate to the Create Node Management Addresses page:

    , then right-click and choose Create Node Management Addresses.

  2. Enter the necessary information on the Create Node Management Addresses page:

    1. In the Select Nodes By field, choose Specific.

    2. In the Nodes area, select the specific nodes for the APICs (shown as controller under the Role column).

    3. In the Config area, choose In-Band Addresses.

    4. In the In-Band Management EPG field, select the default in-band management EPG that you configured in the previous step.

    5. In the In-Band Gateway and In-Band IP Addresses fields, set the in-band gateway and IP address range for the switches.

  3. Click Submit.

Step 7

Configure the inb bridge domain subnet.

  1. Navigate to the Create Subnet page:

    , then right-click and choose Create Subnet.

  2. Enter the necessary info on the Create Subnet page:

    1. In the Gateway IP field, enter the bridge domain subnet that will be used as the gateway for the hardware agent.

    2. In the Scope area, click Advertise Externally.

  3. Click Submit.

Step 8

Verify that the configurations have been completed successfully thus far.

  1. Navigate to the Node Management Addresses page for the leaf and spine switches:

  2. In the area, verify that the leaf and spine switches are listed correctly in the In-Band Management IP and In-Band Management Gateway column.

  3. Verify that the APIC and the switches can ping each other:

Step 9

Configure the L3Out EPG.

  1. Navigate to the L3 Outside page:

    , then right-click and choose Create L3Out.

  2. Enter the necessary information in the Create L3Out wizard, specifically:

    • In the Name field, enter a name for this L3Out (for example, L3Out-mgmt).

    • In the VRF field, select inb:mgmt.

    • In the External EPG pane, configure an external EPG for the L3Out.

Step 10

Create a contract between the L3Out EPG and the in-band management EPG.

  1. Navigate to the Create Contract page for the L3Out EPG:

    , then right-click and choose Create Contract.

  2. Enter the necessary information in the Create Contract page, then click Submit.

  3. Navigate to the External Network Instance Profile page for the L3Out EPG:

  4. In the External Network Instance Profile page for the L3Out EPG, choose the contract that you just created in the Provided Contracts area.

  5. Navigate to the In-Band EPG page for the in-band management EPG:

  6. Choose the contract that you just created in the Consumed Contracts area.

Step 11

Configure the inb bridge domain for the L3Out.

  1. Navigate to the Bridge Domain - inb page:

  2. Click the Policy tab, then the L3 Configurations subtab.

  3. Click Add (+) in the Associated L3Outs area and choose the L3Out that you configured in Step 9.

  4. Click Submit.

Step 12

Verify that the switches can ping the telemetry collector IP address.

Step 13

From the telemetry collector, download the hardware agent (RPM).

  1. In the telemetry collector, click the Action icon, choose Agent Config, then click the Hardware Agent Download tab.

  2. Locate the row with the latest version of the hardware agent and click the Download button in that row.

Step 14

Upload the hardware agent onto the APIC.

  1. In the APIC GUI, navigate to:

  2. Click the Actions button and choose Add Firmware to APIC.

  3. In the Firmware Image Location field, select Local.

  4. In the File Name field, click Browse and navigate to the location on your computer where you downloaded the hardware agent in the previous step.

  5. Select that downloaded file, then click Submit on the Add Firmware to APIC page.

Step 15

Understand the upcoming steps on enabling leaf switches for analytics.

Before going through the next few steps in these procedures, it s helpful to understand what you will be doing and why.

  • Telemetry collection is supported only on EX-model switches and later.

  • EX/FX/FX2 model switches can run in one of these modes:

    • Analytics Priority

    • Netflow Priority

    • Telemetry Priority

    Analytics Priority is the mode used for telemetry collection, so this will be the mode that you will select in the upcoming steps.

  • You will create a Node Control Policy to enable Analytics Priority for consistency.

  • You will configure Node Control Policies under the Fabric Policies.

The following figure shows how the components that you will be configuring in the upcoming steps tie in with one another.

Enabling Leaf Switches For Analytics

 

Step 16

Configure the fabric node control policy.

  1. In the APIC interface, navigate to:

  2. In the Feature Selection area, click Analytics Priority.

    Analytic priority downloads the telemetry sensor software for installation on the switches.

  3. Click Submit.

Step 17

Create an analytics policy.

  1. In the APIC interface, navigate to:

    , then right-click and choose Create Analytics Policy.

  2. On the Create Analytics Policy page, enter the necessary information to create the analytics policy.

  3. Click Submit.

Step 18

Create a leaf and spine switch policy group.

  1. In the APIC interface, navigate to the Create Leaf Switch Policy Group page:

    , then right-click and choose Create Leaf Switch Policy Group.

  2. On the Create Leaf Switch Policy Group page, enter the necessary information, specifically the following fields:

    • Analytics Policy: Select the analytics policy that you created in the previous step.

    • Node Control Policy: Select the default fabric node control policy that you configured in Step 16.

  3. Click Submit.

  4. Navigate to the Create Spiue Switch Policy Group page:

    , then right-click and choose Create Spine Switch Policy Group.

  5. In the Create Spine Switch Policy Group page, enter the necessary information, specifically the following fields:

    • Analytics Policy: Select the analytics policy that you created in the previous step.

    • Node Control Policy: Select the default fabric node control policy that you configured in Step 16.

  6. Click Submit.

Step 19

Create the leaf and spine switch profiles.

  1. In the APIC interface, navigate to the Create Leaf Switch Profile page:

    , then right-click and choose Create Leaf Switch Profile.

  2. On the Create Leaf Switch Profile page, enter the necessary information, specifically the following fields:

    • Switch Associations: Select the leaf switches and associate the leaf switch policy group that you created in the previous step.

  3. Click Submit.

  4. Navigate to the Create Spine Switch Profile page:

    , then right-click and choose Create Spine Switch Profile.

  5. On the Create Spine Switch Profile page, enter the necessary information, specifically the following fields:

    • Switch Associations: Select the spine switches and associate the spine switch policy group that you created in the previous step.

  6. Click Submit.

Step 20

Verify the configurations were set correctly.

  1. Log into the APIC CLI and enter the following:

  2. Log into the leaf switch and enter the following:

Step 21

Verify the configuration.

  1. In the telemetry collector, click the Action button, choose Agent Config, then click the Hardware Agent Conig tab.

    The leaf and spine switches should be displayed in this screen.

Источник: https://www.cisco.com/c/en/us/td/docs/security/workload_security/tetration-analytics/sw/config/cisco-aci-in-band-management-configuration-for-cisco-tetration.html

The Government of New Brunswick believes that, in most cases, employers and their candidates can complete and submit provincial immigration applications without the services of an immigration consultant, an HR recruiter, or other service provider. Indeed, all provincial immigration program guides and necessary application forms are available on this website. And if you have specific questions or concerns, you can write to [email protected] or call 1-506-453-3981.

In many situations, however, you may choose to use a representative to provide immigration advice or assistance with your immigration and other workforce needs.

 

Choosing an authorized immigration consultant

If you do decide to use the services of an immigration consultant or other representative, be sure to choose an authorized, reputable agency or individual, and remember, only the following can charge a monetary fee for immigration support services:

  • Lawyers and paralegals, who are members in good standing of a Canadian provincial or territorial law society;
  • Notaries who are members in good standing of the Chambre des notaires du Québec; and
  • Registered Canadian immigration consultants in good standing with the Immigration Consultants of Canada Regulatory Council (ICCRC)

Consult the ICCRC Registry to find a consultant in your region, or to verify the status of your chosen consultant.

 

Choosing an Authorized HR Professional

In Canada, human resources and recruitment officers identify and advertise job vacancies, recruit candidates, and assist in the selection and reassignment of employees. The role usually requires a university degree or college diploma in a field related to personnel management such as business administration, industrial relations, commerce or psychology or completion of a professional development program in personnel administration, and certification as a Certified Human Resources Professional (CHRP) may be required. CPHR New Brunswick does have a public member list that you can consult to confirm accreditation.


Protect yourself against fraud:

As a general rule, an immigration consultant is not an HR professional and an HR professional is not an immigration consultant (although some professionals or organizations are authorized to offer both suites of services).

  • An immigration consultant can provide you with information and advice about Canadian immigration programs and their processes. An immigration consultant can also assist you with the preparation of any immigration applications.
  • An immigration consultant cannot guarantee the success of your application; they cannot guarantee the speed at which your application will be processed; and they cannot guarantee the reversal of any unfavourable decision that might be delivered upon your application.
  • An HR professional or other recruiter can provide services to help find skilled talent or employment opportunities, but they cannot provide any services related to immigration and its processes.

If an immigration consultant, an HR professional, or any other individual instructs you, or if you of your own accord choose to lie or provide false or misleading information on any immigration application, or if any individual does so on your behalf, all could face criminal charges for misrepresentation and your candidates may be prevented from applying for Canadian permanent residence.

If any individual or company approaches you with claims that they have candidates ready for your business, this is ared flag and you should use caution. It is highly probable that the individual or company has candidates who have paid to get a pathway to Canadian permanent residence – by any means necessary – and so the hired individual or company will “shop around” to find employers willing support immigration via the Atlantic Immigration Pilot Program or New Brunswick Provincial Nominee Program.

If you have concerns about a consultant or recruiter and their practices, or if any individual or company asks to be granted access to your INB Employer account, please contact Population Growth Division immediately at [email protected] or 1-506-453-3981.
 

Источник: https://www.welcomenb.ca/content/wel-bien/en/information_employers/content/recruiters_consultants.html
24 hours Banking - IDBI Bank Internet Banking

With the rapid digitalization that is happening around and with Internet becoming an essential part of our routine lives, Banking on Internet Platform assumes a special significance. IDBI Bank provides its customers, 24 hours online banking services - anytime, anywhere with its Internet Banking.

Now, your bank has a new address. Perform all your banking transactions like Account Information, Demat Account Information, Online instructions, Requests, Bill payments and other merchant payments, from the comfort of your home or office.

Agreeably, such a service requires security of the highest nature and complete privacy protection. Thus, we provide a completely secure environment, using 128-bit encryption SSL (Secure Sockets Layer), digitally certified by VeriSign. 128-bit SSL ensures world-class security for Internet and e-commerce transactions.

Account Information:

  • Account balance
  • Account related enquiries and status
  • Transaction tracking and history
  • Loan Installments and funds flow details
  • Statements
  • Cheque status

Demat Account Information:

  • Demat Account Details displays the name, correspondence address, account numbers and bank account numbers associated with the account.
  • Holding Statements displays the list of demat scrip with ISIN code, scrip name, and balance.
  • Statement of Transaction lists the transactions for a period, with details of security and balances.
  • Billing statement details the charges for respective transactions.

Online Instructions and Requests:

  • Cheque book
  • Stop payment
  • Fixed and Recurring deposit opening / renewal
  • Mobile / DTH recharge
  • IPO application through ASBA

Online Payment Services:

Internet Banking offers online payment facility linked with merchant websites/e-shops through its direct debit payment gateway service. The Bank offers this facility to online merchants/service providers requiring online payment services such as e-commerce merchants, Online Share Trading portals, an AMC selling Online Mutual Funds etc.

Bill Payment and Presentment:

EBPP - Electronic Bill Presentment and Payment feature allows IDBI Bank customers to pay for their utility bills online through the Bank's Internet Banking service or also by visiting the website of the service provider.



How To Apply

Get a Internet Banking in 3 easy steps.

01. Get In Touch

Call on our Phone Banking numbers Toll Free -
1800-209-4324
1800-22-1070 (24x7 service)

03. Receive a Call Back

Our representative will contact you at the earliest.

Get In Touch

Источник: https://www.idbibank.in/idbi-bank-internet-banking.aspx

Mixed Coins INB Certified - (Super Cheap!)

A dealer we do a lot of business with sent us a huge package of coins to go through and said "make an offer." We made a low offer and we were surprised that he took it... Since we got these so cheap, we are going to offer them to you for a price that you likely will not believe.

We can sell you these pieces for LESS than it would cost to actually get them graded. The deal contains a nice mix of Pennies, Nickels, Dimes, Quarters, Half Dollars, Dollars etc. Some of the coins include Wheat Pennies, V Nickels, Buffalo Nickels, Steel Pennies, Indian Head Cents, Kennedy Half Dollars and much more! There are even some Silver Coins are in there!

All coins are graded and identified by the International Numismatic Bureau. We don’t have time to sort through these so we are selling them at $9.95 per coin across the board. Our lack of time, is your gain! We will send you a very nice assortment of types of coins and denominations.

Highlights

  • Nice variety
  • Individually authenticated
  • The perfect collectible

*You will receive (1) coin per order. If you buy multiples, we will send you a variety.*

Источник: https://bullionsharks.com/mixed-coins-inb-certified-super-cheap/

ABOUT US

Irfan Noman Brothers (Pvt) Ltd is the 3rd generation in rice business. The first Rice Mill was established in 1964 by the founding group Chairman, Mr. Mukhtar Ahmed Sheikh who was at that time, the Chairman, Rice Millers and Supplier Association & member of the Rice Board (Government of Pakistan Rice Committee), after which Irfan Noman group installed three additional Rice Mills in different parts of the country and started rice farming in over 1000 Acers of agricultural land. Irfan Noman Brothers currently have two units in operation 1st one is in S.I.T.E with capacity to process 1,25,000 metric tons per year & 2nd unit at Port Qasim eastern zone spread over 10 Acers of land with a capacity to process 3,00,000 Metric Tons at our latest bhular plant with state of the art sortex machine from sortex U.K. Another warehouse facility is also under construction at our Punjab facility on 12 Acre of land at FIEDMC Faisalabad to cater the Basmati buyers.

Exports During 2019 – 2020: INB has a turnover of Pak RS 8 billion during the year 2019~2020 with export value of 1, 25,000 Metric Ton.

UNIT 1: INB Rice Mill PORT QASIM is spread on 10 Acres of land with warehouse of over 200,000 sq feet, with production capacity of 20 Tons per hour which comes to 175000 metric tons per year which is being converted into 40 Tons per hour in next 6 month which comes to 350000 metric tons per year. Our new mill is also equipped with the state of art machinery imported from BUHLER, Germany comprising cleaner, de-stoners, and set of polishers to ensure homogeneous whiteness on rice up to 46 Kett along with the 7 most modern color sorter machines from sortex. The plant is strictly according to ISO-9001:2008 standards and H.A.C.C.P. standards.

UNIT 2: INB Rice Mill S.I.T.E is equipped with the state of art machinery imported from BUHLER, Germany comprising cleaner, de-stoners, and set of polishers to ensure homogeneous whiteness on rice up to 46 Kett along with the 3 most modern color sorter machines from sortex. INB has its own Power Generation, having capacity to process 1,25,000 metric tons rice per year. The plant is strictly according to ISO-9001:2008 standards and H.A.C.C.P. standards.

UNIT 3: INB FIEDMC spread over of 12.5 Acre of land with state of the art storage facility in Punjab is also under construction to capture Brown Basmati Rice market for Europe and will also have parboiled and steaming facilities.

INB DUBAI OFFICE: In order to have a strong market presence in the Gulf region, Irfan Noman Brothers (Pvt.) Ltd. have established a marketing office and warehouse right in the heart of Dubai, UAE. In 2007, we identified the gap in the Middle Eastern rice market and opened our shop in Dubai where ready stocks are always available to cater the immediate demands of the customers in UAE.

Canada Office: INB Canada Office look after North America Market & look after our famous Mehman Brand sales in North American Territories for last 5 years.

Mehman Outlets:  INB also had its own outlets in different places of city to sell our Premium Brand of Basmati Rice in domestic markets for last 15 years.

Brand of the year Award:  Our famous brand “Mehman” is also the recipient of best brand of the year award from prime minister of Pakistan.

Certification:H.A.C.C.P certification of UK, ISO-9001:2008 certified from UK, HALAL Certified Company, Also in process of G.M.P Certification

VISION: We, at Irfan Noman Brothers (Pvt.) Ltd., being one of the top exporters of rice from Pakistan aspire to carve a niche for ourselves in the rice industry by becoming international market leaders and also by providing our customers with the best quality product.

MISSION: Dedicated to positioning our brand internationally, this adheres to high quality standards whilst providing superior products and services to our valuable customers.

Источник: https://www.inbrice.com/about-us/

     

Exhibit 10.1

SEPARATION AND DISTRIBUTION AGREEMENT

THIS SEPARATION AND DISTRIBUTION AGREEMENT (this “Agreement”) is entered into as of November 14, 2007, between Integrated BioPharma, Inc., a Delaware corporation (“INB”), and InB:Biotechnologies, Inc., a New Jersey corporation (“Biotech”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in Article 6 hereof.

RECITALS

WHEREAS, INB currently owns a majority of the issued and outstanding common stock of Biotech;

WHEREAS, Biotech is engaged in the specialty pharmaceutical business and related businesses as described in the Information Statement that is an exhibit to the Form 10 to be filed by Biotech with the Securities and Exchange Commission (the “Biotech Business”);

WHEREAS, the Boards of Director of INB has determined that it would be appropriate and desirable for INB to distribute, pro rata, to the holders of its common stock, all of the shares of Biotech common stock owned by INB (the “Distribution”);

WHEREAS, subsequent to the Distribution, and as provided for in this Agreement, Biotech will be an independent public company (the “Separation”); and

WHEREAS, INB and Biotech intend that the Separation and the Distribution will qualify as a tax-free reorganization under Section 355 of the Internal Revenue Code of 1986, as amended (the “Code”).

NOW, THEREFORE, in consideration of the foregoing and the covenants and agreements set forth below, the parties hereto agree as follows:

1.     SEPARATION

1.1.     Distribution Date. Unless otherwise provided in this Agreement, or in any agreement to be executed in connection with this Agreement, the effective time and date of the Distribution, and each undertaking or agreement in connection therewith shall be such date as may be fixed by the Board of Directors of INB following satisfaction of the conditions to the Distribution set forth in Section 3.9 (the “Distribution Date”).


1


1.2.     Closing of Transactions. Unless otherwise provided herein, the closing of the transactions contemplated in Article 2 shall occur on the Distribution Date. Executed copies of each of the Ancillary Agreements and any other agreements or documents executed in connection with the transaction contemplated hereby, or thereby, shall be held in escrow by Greenberg Traurig, LLP (the “Escrow Agent”) for delivery as provided in Section 1.3.

1.3.     Exchange of Secretary’s Certificates. Upon receipt of a certificate of the Secretary or an Assistant Secretary of INB in form satisfactory to the Escrow Agent, the Escrow Agent shall deliver to Biotech on behalf of INB all of the items required to be delivered by INB hereunder pursuant to Section 2.1 and each such item shall be deemed to be delivered to Biotech as of the Distribution Date upon delivery of such certificate. Upon receipt of a certificate of the Secretary or an Assistant Secretary of Biotech in form satisfactory to the Escrow Agent, the Escrow Agent shall deliver to INB on behalf of Biotech all of the items required to be delivered by Biotech pursuant to Section 2.2 hereunder and each such item shall be deemed to be delivered to INB as of the Distribution Date upon receipt of such certificate.  

2.     DOCUMENTS TO BE DELIVERED ON THE DISTRIBUTION DATE  

2.1.     Documents to Be Delivered by INB. On the Distribution Date or such other date as may be established by the board of directors of INB, or as otherwise agreed by the parties, INB will deliver to Biotech all of the following items and agreements, in each case in form and substance customary for a transaction structured like the Distribution and as mutually agreed upon by INB and Biotech (collectively, together with all agreements and documents contemplated by such agreements, the “Ancillary Agreements”):

(a)     A duly executed Tax Sharing Agreement, in the form attached hereto as Exhibit 1;

(b)     A duly executed Transitional Services Agreement, in the form attached hereto as Exhibit 2;

(c)     A duly executed Confidentiality and Nondisclosure Agreement, in the form attached hereto as Exhibit 3;

(d)     A duly executed Indemnification and Insurance Matters Agreement, in the form attached hereto as Exhibit 4;

(e)     Such other agreements, documents or instruments as the parties may agree are necessary or desirable in order to achieve the purposes hereof.


2


2.2.     Documents to Be Delivered by Biotech. As of the Distribution Date, Biotech will deliver to INB each of the Ancillary Agreements.

3.     THE DISTRIBUTION

3.1.     Delivery of Shares for Distribution. On or prior to the Distribution Date, INB will deliver to the distribution agent for the Distribution (the “Distribution Agent”) and the INB transfer agent, a single stock certificate, endorsed by INB, representing all of the outstanding shares of common stock of Biotech then owned by INB. The shares of Biotech common stock represented by said certificate shall be the shares distributed to the stockholders of INB, pursuant to the Distribution. INB shall cause the Distribution Agent to distribute on the Distribution Date the appropriate number of such shares of common stock of Biotech to each shareholder of INB as of the record date of the Distribution to be set by INB, or the designated transferee or transferees of such shareholder. 

3.2.     Shares Received. Subject to Sections 4.4 and 4.5, each holder of common stock of INB on the Record Date (or such holder’s designated transferee or transferees) will be entitled to receive in the Distribution a number of shares of common stock of Biotech equal to the number of shares of common stock of INB held by such holder on the Record Date. The amount of shares issued and outstanding to the individual shareholders of Biotech holding such shares prior to the Distribution Date shall not be increased or reduced by the Distribution.

3.3.     Obligation to Provide Information. Biotech and INB, as the case may be, will provide to the Distribution Agent all share certificates and any information required in order to complete the Distribution on the basis specified above.

3.4.     Information Statement. Prior to the Distribution Date, INB and Biotech shall prepare and mail, to the holders of common stock of INB such information concerning Biotech and the Distribution and such other matters as INB shall reasonably determine are necessary and as may be required by law. INB and Biotech will prepare, and Biotech will, to the extent required under applicable law, file with the Securities and Exchange Commission any such documentation that INB and Biotech determine is necessary or desirable to effectuate the Distribution, and INB and Biotech shall each use its reasonable commercial efforts to obtain all necessary approvals from the Commission with respect thereto as soon as practicable.

3.5.     Blue Sky. INB and Biotech shall take all such actions as may be necessary or appropriate under the securities or blue sky laws of the United States (and any comparable laws under any foreign jurisdiction) in connection with the Distribution.


3


3.6.     Nasdaq Listing. Biotech shall prepare and file, and shall use its reasonable commercial efforts to have approved, an application for the additional listing of the common stock of Biotech to be distributed in the Distribution on the Nasdaq Capital Market, or such other national stock exchange as determined by Biotech’s Board of Directors, subject to official notice of distribution.

3.7.     Conditions. INB and Biotech shall take all reasonable steps necessary and appropriate to cause the conditions set forth in Section 3.9 to be satisfied and to effect the Distribution on the Distribution Date. 

3.8.     Sole Discretion of INB. INB agrees to use commercially reasonable efforts to complete the Distribution on or before February 1, 2008. INB shall, in its sole and absolute discretion, determine the date of the consummation of the Distribution and all terms of the Distribution, including, without limitation, the form, structure and terms of any transaction(s) and/or offering(s) to effect the Distribution and the timing of and conditions to the consummation of the Distribution. In addition, INB may at any time and from time to time until the completion of the Distribution, modify or change the terms of the Distribution, including, without limitation, by accelerating or delaying the timing of the consummation of all or part of the Distribution. Biotech shall cooperate with INB in all respects to accomplish the Distribution and shall, at INB’s direction, promptly take any and all actions necessary or desirable to effect the Distribution. INB shall select any financial printer, distribution agent and outside counsel for INB; provided, however, that nothing herein shall prohibit Biotech from engaging (at its own expense) its own financial, legal, accounting and other advisors in connection with the Distribution.

3.9.     Conditions Precedent to Distribution. The following are conditions that must take place prior to the consummation of the Distribution. The conditions are for the sole benefit of INB and shall not give rise to or create any duty on the part of INB or the INB Board of Directors to waive or not waive any such condition.

(a)     Form 10. The Form 10 to be filed by Biotech shall be effective under the Exchange Act, with no stop order in effect with respect thereto.

(b)      Tax Opinion. INB shall have obtained an opinion letter from Greenberg Traurig, LLP in form and substance satisfactory to INB (in its sole discretion), and such letter shall remain in effect as of the Distribution Date, to the effect that the distribution by INB of all of its Biotech stock to the stockholders of INB should qualify as a tax free transaction under Section 355 of the Code.


4


(c)     Government Approvals. Any material governmental approvals and consents necessary to consummate the Distribution, including without limit a declaration by the SEC of the effectiveness of the registration of the Biotech common stock on Form 10, shall have been obtained and be in full force and effect.

(d)     Listing of BiotechStock. Biotech shall have received the approval by Nasdaq or a national stock exchange for the listing of the Biotech common stock on the Nasdaq Capital Market, or national stock exchange.

(e)     No Legal Restraints. No order, injunction or decree issued by any court or agency of competent jurisdiction or other legal restraint or prohibition preventing the consummation of the Distribution shall be in effect and no other event outside the control of INB shall have occurred or failed to occur that prevents the consummation of the Distribution.

(f)     No Material Adverse Effect. No events or developments other than the Distribution itself shall have occurred subsequent to the Record Date that, in the judgment of the Board of Directors of INB, would result in the Distribution having a material adverse effect on INB or on the stockholders of INB.

(g)     Ancillary Agreements. Each Ancillary Agreement shall be duly executed and delivered and be in full force and effect.

(h)     Conversion of Debt to Equity. Simultaneous with the Distribution, Biotech shall have converted a portion of the debt owed to INB into equity of Biotech, such that INB shall hold shares of Common Stock of Biotech representing 6% of the issued and outstanding shares of Biotech Common Stock subsequent to the distribution.

4.     COVENANTS AND OTHER MATTERS

4.1.     Required Consent. To preserve the tax free character of the Distribution, for the two years immediately following the effective date of the Distribution Date, Biotech may not issue any additional shares of its common stock in excess of the shares issued with respect to the Distribution, nor enter into any agreement, arrangement or understanding with any Person that contemplates a transaction, which would, singly or in combination with any other issuance or transaction, result in a change in 50% or more of the direct or indirect ownership of the Biotech common stock from said ownership as constituted on the Distribution Date. If the Biotech Board of Directors, by a written vote or unanimous consent, determine that such issuance or transaction is in the best interest of the Biotech shareholders, the Chairman of Biotech may submit a request for the consent of the INB Board to effect such issuance or enter into such transaction. Such request shall be in writing, addressed to the Chairman of the INB Board of Directors, setting forth the details of the proposed issuance or transaction, the benefits accruing to the Biotech shareholders in connection therewith, and such assurances and security regarding the possible tax


5


liability that could be engendered by the proposed issuance or transaction. The INB Board may, in its sole and absolute discretion, by resolution at a meeting duly called and held or by unanimous written consent, consent to or elect to withhold their consent to such proposed issuance or transaction. The requirement under this Section 4.1 to obtain the consent of the INB Board to any proposed issuance or transaction shall cease on the second anniversary of the Distribution, and shall thereafter be of no further force or effect.

4.2.     Other Agreements. INB and Biotech agree to execute or cause to be executed by the appropriate parties and deliver, as appropriate, such other agreements, instruments and other documents as may be necessary or desirable in order to effect the purposes of this Agreement and the Ancillary Agreements.

4.3.     Additional Transitional Services Agreements. INB and Biotech will enter into the Transitional Services Agreement covering the provision of various transitional services by INB for Biotech, including SEC reporting, internal auditing and financial, accounting, legal, real estate and such other services Biotech may wish to obtain from INB. Such services will generally be provided for a fee that will be approximately equal to the direct costs and indirect costs of providing such services plus five percent (5.0%). The transitional services agreement will generally provide for a term of three years, or less.

4.4.     Agreement for Exchange of Information.

(a)     Generally.


6


(b)     Internal Accounting Controls; Financial Information. After the Distribution Date, (i) each party shall maintain in effect at its own cost and expense adequate systems and controls for its business to the extent necessary to enable the other party to satisfy its reporting, accounting, audit and other obligations, and (ii) each party shall provide, or cause to be provided, to the other party and its Subsidiaries in such form as such requesting party shall request, at no charge to the requesting party, all financial and other data and information as the requesting party determines necessary or advisable in order to prepare its financial statements and reports or filings with any Governmental Authority.

(c)     Ownership of Information. Any Information owned by a party that is provided to a requesting party pursuant to this Section 4.4 shall be deemed to remain the property of the providing party. Unless specifically set forth herein, nothing contained in this Agreement shall be construed as granting or conferring rights of license or otherwise in any such Information.

(d)     Record Retention. To facilitate the possible exchange of Information pursuant to this Section 4.4 and other provisions of this Agreement after the Distribution Date, each party agrees to use its reasonable commercial efforts to retain all Information in its respective possession or control on the Distribution Date substantially in accordance with the policies of INB as in effect on the Distribution Date. However, except as set forth in the Tax Sharing Agreement, at any time after the Distribution Date, each party may amend its respective record retention policies at such party’s discretion; provided, however, that if a party desires to effect the amendment within three (3) years after the Distribution Date, the amending party must give thirty (30) days prior written notice of such change in the policy to the other party to this Agreement. No party will destroy, or permit any of its Subsidiaries to destroy, any Information that exists on the Distribution Date (other than Information that is permitted to be destroyed under the current record retention policies of INB) and that falls under the categories listed in Section 4.4(a), without first using its reasonable commercial efforts to notify the other party of the proposed destruction and giving the other party the opportunity to take possession of such Information prior to such destruction.

(e)     Limitation of Liability. No party shall have any liability to any other party in the event that any Information exchanged or provided pursuant to this Section 4.4 is found to be inaccurate, in the absence of gross negligence or willful misconduct by the party providing such Information. No party shall have any liability to any other party if any Information is destroyed or lost after reasonable commercial efforts by such party to comply with the provisions of Section 4.4(d).

(f)     Other Agreements Providing for Exchange of Information. The rights and obligations granted under this Section 4.4 are subject to any specific limitations, qualifications or additional provisions on the sharing, exchange or confidential treatment of Information set forth in this Agreement and any Ancillary Agreement.


7


(g)     Production of Witnesses; Records; Cooperation. After the Distribution Date, except in the case of a legal or other proceeding by one party against another party (which shall be governed by such discovery rules as may be applicable under Section 4.9 or otherwise), each party hereto shall use its reasonable commercial efforts to make available to each other party, upon written request, the former, current and future directors, officers, employees, other personnel and agents of such party as witnesses and any books, records or other documents within its control or which it otherwise has the ability to make available, to the extent that any such person (giving consideration to business demands of such directors, officers, employees, other personnel and agents) or books, records or other documents may reasonably be required in connection with any legal, administrative or other proceeding in which the requesting party may from time to time be involved, regardless of whether such legal, administrative or other proceeding is a matter with respect to which indemnification may be sought hereunder. The requesting party shall bear all costs and expenses in connection therewith.

4.5.     Auditors and Audits; Annual and Quarterly Statements and Accounting. Each party agrees that, for so long as INB under generally accepted accounting principles to consolidate Biotech’s results of operations and financial position within INB’s financial statements:

(a)     Selection of Auditors. Biotech shall not select a different firm of independent certified public accountants that is used by INB to serve as its (and its Subsidiaries’) independent auditors (“Biotech’s Auditors”) for purposes of providing an opinion on its consolidated financial statements without INB’s prior written consent (which shall not be unreasonably withheld, delayed or conditioned).

(b)     Date of Auditors’ Opinion and Quarterly Reviews. Biotech shall use its reasonable commercial efforts to enable the Biotech Auditors to complete their audit such that they will date their opinion on Biotech’s audited annual financial statements on the same date that INB’s independent auditors (“INB’s Auditors”) date their opinion on INB’s audited annual financial statement, and to enable INB to meet its timetable for the printing, filing and public dissemination of INB’s annual financial statements for so long as INB is a publicly traded company. Biotech shall use its reasonable commercial efforts to enable the Biotech Auditors to complete their quarterly review procedures such that they will provide clearance on Biotech’s quarterly financial statements on the same date that INB’s Auditors provide clearance on INB’s quarterly financial statements.


8


(c)     Annual and Quarterly Financial Statements. Biotech shall provide to INB on a timely basis all Information that INB reasonably requires to meet its schedule for the preparation, printing, filing, and public dissemination of INB’s annual and quarterly financial statements for so long as INB is a publicly traded company. Without limiting the generality of the foregoing, Biotech will provide all required financial Information with respect to Biotech and its Subsidiaries to Biotech’s Auditors in a sufficient and reasonable time and in sufficient detail to permit Biotech’s Auditors to take all steps and perform all reviews necessary to provide sufficient assistance to INB’s Auditors with respect to financial Information to be included or contained in INB’s annual and quarterly financial statements. Similarly, INB shall provide to Biotech on a timely basis all financial Information that Biotech reasonably requires to meet its schedule for the preparation, printing, filing, and public dissemination of Biotech’s annual and quarterly financial statements. Without limiting the generality of the foregoing, INB will provide all required financial Information with respect to INB and its Subsidiaries to INB’s Auditors in a sufficient and reasonable time and in sufficient detail to permit INB’s Auditors to take all steps and perform all reviews necessary to provide sufficient assistance to Biotech’s Auditors with respect to Information to be included or contained in Biotech’s annual and quarterly financial statements.

(d)     Identity of Personnel Performing the Annual Audit and Quarterly Reviews. Biotech shall authorize Biotech’s Auditors to make available to INB’s Auditors both the personnel who performed or will perform the annual audits and quarterly reviews of Biotech and work papers related to the annual audits and quarterly reviews of Biotech, in all cases within a reasonable time prior to Biotech’s Auditors’ opinion date, so that INB’s Auditors are able to perform the procedures they consider necessary to take responsibility for the work of Biotech’s Auditors as it relates to INB’s Auditors’ report on INB’s financial statements, all within sufficient time to enable INB to meet its timetable for the printing, filing and public dissemination of INB’s annual and quarterly statements. Similarly, INB shall authorize INB’s Auditors to make available to Biotech’s Auditors both the personnel who performed or will perform the annual audits and quarterly reviews of INB and work papers related to the annual audits and quarterly reviews of INB, in all cases within a reasonable time prior to INB’s Auditors’ opinion date, so that Biotech’s Auditors are able to perform the procedures they consider necessary to take responsibility for the work of INB’s Auditors as it relates to Biotech’s Auditors’ report on Biotech’s statements, all within sufficient time to enable Biotech to meet its timetable for the printing, filing and public dissemination of Biotech’s annual and quarterly financial statements.


9


(e)     Access to Books and Records. Biotech shall provide INB’s internal auditors and their designees access to Biotech’s and its Subsidiaries’ books and records so that INB may conduct reasonable audits relating to the financial statements provided by Biotech pursuant hereto as well as to the internal accounting controls and operations of Biotech and its Subsidiaries. Similarly, INB shall provide Biotech’s internal auditors and their designees access to INB’s and its Subsidiaries’ books and records so that Biotech may conduct reasonable audits relating to the financial statements provided by INB pursuant hereto as well as to the internal accounting controls and operations of INB and its Subsidiaries

(f)     Notice of Change in Accounting Principles. Biotech shall give INB as much prior notice as reasonably practical of any proposed determination of, or any significant changes in, its accounting estimates or accounting principles from those in effect on the Distribution Date. Biotech will consult with INB and, if requested by INB, Biotech will consult with INB’s Auditors with respect thereto. INB shall give Biotech as much prior notice as reasonably practical of any proposed determination of, or any significant changes in, its accounting estimates or accounting principles from those in effect on the Distribution Date.

(g)     Conflict with Third-Party Agreements. Nothing in Sections 4.4 and 4.5 shall require Biotech to violate any agreement with any third party regarding the confidentiality of confidential and proprietary information relating to that third party or its business; provided, however, that in the event that Biotech is required under Sections 4.4 and 4.5 to disclose any such Information, Biotech shall use all commercially reasonable efforts to seek to obtain such third party’s consent to the disclosure of such information.

4.6.     Consistency with Past Practices. At all times, INB and Biotech will conduct the Biotech Business before the Distribution Date in the ordinary course, consistent with past practices.

4.7.     Payment of Expenses. Except as otherwise provided in this Agreement, the Ancillary Agreements or any other agreement between the parties relating to the Distribution, all costs and expenses of the parties hereto in connection with the Distribution shall be borne and paid by INB. Biotech and INB shall each be responsible for their own internal fees, costs and expenses incurred in connection with the Distribution.

4.8.     Governmental Approvals. To the extent that the Distribution requires any Governmental Approvals, the parties will use their reasonable commercial efforts to obtain any such Governmental Approvals.


10


4.9.     Dispute Resolution

(a)     Mediation. With respect to any dispute, claim or controversy between the parties arising out of or relating to this Agreement or any Ancillary Agreement, the parties agree that they will attempt in good faith to resolve the matter through negotiation. Upon mutual agreement of the parties, the matter may be submitted to any mutually agreed-upon mediation service for mediation. Mediation shall be commenced by providing to the mediation service a joint, written request for mediation, setting forth the subject of the dispute and the relief requested. The parties will cooperate with the mediation service and with one another in selecting a neutral mediator and in scheduling the mediation proceedings. The parties covenant that they will use commercially reasonable efforts in participating in the mediation. The parties agree that the mediator’s fees and expenses and the costs incidental to the mediation will be shared equally between the parties. The parties further agree that all offers, promises, conduct and statements, whether oral or written, made in the course of the mediation by any of the parties, their agents, employees, experts and attorneys, and by the mediator and any employees of the mediation service, are confidential, privileged and inadmissible for any purpose, including impeachment, in any litigation or other proceeding involving the parties, provided that evidence that is otherwise admissible or discoverable shall not be rendered inadmissible or non-discoverable as a result of its use in the mediation. Either party may commence an arbitration proceeding in accordance with Section 4.9(b) with respect to the matter submitted to mediation at any time after the completion of the initial mediation session, or ninety (90) days after the date of filing the written request for mediation, whichever occurs first.

(b)     Arbitration. Upon the prior written notice provided by to the other party pursuant to Section 4.9(a), any claim arising out of or related to this Agreement or any Ancillary Agreement, or the default hereof or thereof, which has not been resolved by mediation shall be settled by arbitration, which shall be conducted at in accordance with the rules of the American Arbitration Association then in effect, as modified or supplemented herein, or as the parties mutually agree otherwise. The decision of the arbitrator


11


shall be final, and judgment may be entered upon it in accordance with the applicable law in any court having jurisdiction. Any claim for relief made pursuant to this Agreement shall be made within one (1) year from the date upon which the party claiming relief knew or should have known of the cause of action constituting such claim. The arbitrator or arbitrators may award monetary damages to the prevailing party only for actual damages, but may not award punitive, consequential, special or incidental damages as between the parties. Notwithstanding the above, punitive, consequential special or incidental damages may be awarded if such damages are payable to a third party.

5.     MISCELLANEOUS

5.1.     Limitation of Liability. In no event shall INB, its subsidiaries, and any of their respective officers, directors, employees or agents, or Biotech, its subsidiaries, and any of their respective officers, directors, employees or agents be liable to any other member of INB or Biotech for any special, consequential, indirect, incidental or punitive damages or lost profits, however caused and on any theory of liability (including negligence) arising in any way out of this agreement, whether or not such party has been advised of the possibility of such damages; provided, however, that the foregoing limitations shall not limit each party’s indemnification obligations for liabilities as set forth in the Indemnification and Insurance Matters Agreement.

5.2.     Entire Agreement. This Agreement, the Ancillary Agreements and the Exhibits and Schedules referenced or attached hereto and thereto, constitute the entire agreement between the parties with respect to the subject matter hereof and thereof and shall supersede all prior written and oral and all contemporaneous oral agreements and understandings with respect to the subject matter hereof and thereof.

5.3.     Governing Law. This Agreement shall be construed in accordance with and all Disputes hereunder shall be governed by the laws of the State of Delaware, excluding its conflict of law rules.

5.4.     Termination. This Agreement and all Ancillary Agreements may be terminated and the Distribution abandoned at any time prior to the Distribution Date by and in the sole discretion of INB without the approval of Biotech. In the event of termination pursuant to this Section 5.4, no party shall have any liability of any kind to the other party.


12


5.5.     Notices. Notices, offers, requests or other communications required or permitted to be given by either party pursuant to the terms of this Agreement shall be given in writing to the respective parties to the following addresses:

if to INB :

Integrated BioPharma, Inc.
225 Long Avenue
Hillside, New Jersey 07205

Attention: President

if to Biotech:

InB:Biotechnologies, Inc.

9 Innovation Way, Suite 100

Newark, Delaware 19711

Attention: President

or to such other address as the party to whom notice is given may have previously furnished to the other in writing as provided herein. Any notice involving non-performance, termination, or renewal shall be sent by hand delivery, recognized overnight courier or, within the United States, may also be sent via certified mail, return receipt requested. All other notices may also be sent by fax, confirmed by first class mail. All notices shall be deemed to have been given and received on the earlier of actual delivery or three (3) days from the date of postmark.

5.6.     Counterparts. This Agreement, including the Ancillary Agreements and the Exhibits and Schedules thereto and the other documents referred to herein or therein, may be executed in counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same agreement.

5.7.     Binding Effect; Assignment. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective legal representatives and successors, and nothing in this Agreement, express or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever under or by reason of this Agreement. This Agreement may be enforced separately by INB and Biotech. Neither party may assign this Agreement or any rights or obligations hereunder, without the prior written consent of the other party, and any such assignment shall be void; provided, however, either party may assign this Agreement to a successor entity in conjunction with such party’s reincorporation.


13


5.8.     Severability. If any term or other provision of this Agreement or the Exhibits or Schedules attached hereto is determined by a court, administrative agency or arbitrator to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to either party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that transactions contemplated hereby are fulfilled to the fullest extent possible.

5.9.     Failure or Indulgence Not Waiver; Remedies Cumulative. No failure or delay on the part of either party hereto in the exercise of any right hereunder shall impair such right or be construed to be a waiver of, or acquiescence in, any breach of any representation, warranty or agreement herein, nor shall any single or partial exercise of any such right preclude other or further exercise thereof or of any other right. All rights and remedies existing under this Agreement or the Exhibits or Schedules attached hereto are cumulative to, and not exclusive of, any rights or remedies otherwise available.

5.10.     Amendment. No change or amendment will be made to this Agreement or the Exhibits or Schedules attached hereto except by an instrument in writing signed on behalf of each of the parties to such agreement.

5.11.     Authority. Each of the parties hereto represents to the other that (a) it has the corporate or other requisite power and authority to execute, deliver and perform this Agreement, (b) the execution, delivery and performance of this Agreement by it have been duly authorized by all necessary corporate or other actions, (c) it has duly and validly executed and delivered this Agreement, and (d) this Agreement is a legal, valid and binding obligation, enforceable against it in accordance with its terms subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and general equity principles.

5.12.     Interpretation. The headings contained in this Agreement, in any Exhibit or Schedule hereto and in the table of contents to this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Any capitalized term used in any Exhibit or Schedule but not otherwise defined therein, shall have the meaning assigned to such term in this Agreement. When a reference is made in this Agreement to an Article or a Section, Exhibit or Schedule, such reference shall be to an Article or Section of, or an Exhibit or Schedule to, this Agreement unless otherwise indicated.


14


5.13.     Conflicting Agreements. In the event of conflict between this Agreement and any Ancillary Agreement or other agreement executed in connection herewith, the provisions of such other agreement shall prevail.

5.14     Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person; provided, however, that any investor acquiring shares of Common Stock of Biotech prior to the Distribution Date shall be an intended beneficiary of this Agreement.

6.     DEFINITIONS

6.1.     Biotech. “Biotech” means Biotech, each subsidiary of Biotech as of the date of this Agreement and as of the Distribution Date, and any time thereafter the Distribution Date, and each Person that becomes a Subsidiary of Biotech after the Distribution Date.

6.2.     Biotech’s Auditors. “Biotech’s Auditors” means Biotech’s independent certified public accountants.

6.3.     Distribution Date. “Distribution Date” has the meaning set forth in the Section 1.1 hereof.

6.4.     Governmental Approvals. “Governmental Approvals” means any notices, reports or other filings to be made, or any consents, registrations, approvals, permits or authorizations to be obtained from, any Governmental Authority.

6.5.     Governmental Authority. “Governmental Authority” shall mean any federal, state, local, foreign or international court, government, department, commission, board, bureau, agency, official or other regulatory, administrative or governmental authority.

6.6.     INB. “INB” means INB, each subsidiary of INB (other than Biotech) as of the date of this Agreement and from and after the Distribution Date, and each Person that becomes a Subsidiary of INB after the Distribution Date.

6.7     INB’s Auditors. “INB’s Auditors” means INB’s independent certified public accountants.


15


6.8.     Information. “Information” means information, whether or not patentable or copyrightable, in written, oral, electronic or other tangible or intangible forms, stored in any medium, including studies, reports, records, books, contracts, instruments, surveys, discoveries, ideas, concepts, know-how, techniques, designs, specifications, drawings, blueprints, diagrams, models, prototypes, samples, flow charts, data, computer data, disks, diskettes, tapes, computer programs or other software, marketing plans, customer names, communications by or to attorneys (including attorney-client privileged communications), memos and other materials prepared by attorneys or under their direction (including attorney work product), and other technical, financial, employee or business information or data.

6.9.     Person. “Person” means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.

6.10.     Record Date. “Record Date” means the record date for the Distribution to be set by the INB Board of Directors.

6.11.     Subsidiary. “Subsidiary” of any Person means a corporation or other business organization whether incorporated or unincorporated of which at least a majority of the securities or interests having by the terms thereof ordinary voting power to elect at least a majority of the board of directors or others performing similar functions with respect to such corporation or other organization is directly or indirectly owned or controlled by such Person or by any one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries; provided, however, that no Person that is not directly or indirectly wholly-owned by any other Person shall be a Subsidiary of such other Person unless such other Person controls, or has the right, power or ability to control, that Person.


16


WHEREFORE, the parties have signed this Separation and Distribution Agreement effective as of the date first set forth above.

INTEGRATED BIOPHARMA, INC.



INB:BIOTECHNOLOGIES, INC.


17

Источник: https://ir.ibioinc.com/sec-filings/content/0001420720-08-000003/exhibit10_1.htm

Our certifications

 

 

 

Synergie is developing a policy of commitment among its employees, with the aim of satisfying as many of its customers and temporary workers as possible. This policy has been recognised by external organisations through various certifications that confirm Synergie's wide range of expertise.

 

 

ISO Version 2008 certification

Our provision of this service is certified ISO version 2008.
Since 1996, we have been relying on our quality management system to continuously improve the satisfaction of our customers and temporary workers, and to guarantee reliable and consistent service throughout France.

In addition to annual audits conducted by AFNOR, a team of seven auditors operating throughout France supports our teams with the continuous improvement of their work, in order to ensure:
- a selection of candidates based on reliable criteria,
- the monitoring of the proper completion of temporary workers' assignments,
- the administrative management of personnel members, in accordance with labour regulations,
- the provision of statistics.

 

 

Источник: https://www.synergie.com/en/csr-policy/certifications

4 Replies to “Inb certified”

  1. Aapke bhale ke liye bol raha tha, bohot saare fraud ho rahe hai, that's why.... So if don't want to share that's OK... No problem, aage apka final selection hoga... Or uske baad aapko apna appointment letter diya jayega or chota sa ek Training provide kiya jayega...

  2. I've been watching this video frequently these last few days. I'm up for a pretty big promotion at work and I wanted to be as prepared as possible. I interviewed today and they make a decision in a few days! Fingers crossed!

Leave a Reply

Your email address will not be published. Required fields are marked *